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BACKGROUND 
 
Estimates of the costs of implementing health interventions are required for informing a wide range 
of decisions in global health. Costs are used in economic evaluations, such as benefit-cost or cost-
effectiveness analysis, and other economic analyses to inform priority setting.  Cost interventions 
are also needed for financial planning and management, and the formulation of resource 
requirements and budgets. In addition, cost estimates can provide additional detail on how 
interventions are implemented, which can be useful for assessing the efficiency of service delivery.   
Costs are typically estimated using a range of approaches and assumptions, often combining data 
obtained as part of research studies with data collected as part of routine program implementation.  
While numerous textbooks and guideline documents exist, analysts apply and interpret such 
guidance based on their prior training, professional experience, and context. However, there is no 
widely agreed-upon common guidance on principles, methods, and reporting standards specifically 
aimed at cost estimation across global health. 
The variation in applying the methods and reporting of costs for global health interventions has long 
been recognized1-3. This variation can have an impact on estimates of cost-effectiveness, which 
should be comparable across interventions4,5. A review of economic evaluations in the Tufts Medical 
Center Cost-Effectiveness Analysis (CEA) Registry found a high level of variation in costing methods, 
although the review noted an improvement in consistency over time6. Differences in data collection 
methods and in the application of analytic methods, a general lack of comprehensiveness, and 
inconsistent compliance to existing guidance were all observed7. As a result, reviews of global health 
costs conclude that methodological heterogeneity and lack of transparency make it impossible to 
compare studies over setting and time8-11, and several papers point to the need to develop 
standardized methods for cost estimation in global health12.  
Aims 
 
The goal of the ‘Reference Case for Estimating the Costs of Global Health Services and Interventions’ 
is to improve the quality of cost estimates through improved consistency and transparency of 
methods, assumptions, and reporting. The Reference Case is a guide that helps ensure that the 
process of cost estimation is clearly conveyed and reflects best practices, so that those using cost 
data can interpret the findings properly and assess their quality (accuracy, precision, generalizability, 
and consistency). The Reference Case provides a practical framework for analysts to ensure that 
they consider how methods may influence estimates and thereby improve the interpretation and 
use of cost data.  
The reference case approach has its origins in the field of economic evaluation. The first US Panel on 
Cost-Effectiveness in Health and Medicine (‘US Panel’) proposed the use of a reference case “to 
improve comparability of cost-effectiveness analyses designed to inform decision-making while 
allowing analysts the flexibility to design studies that answer issues specific to a particular problem 
or industry”. This concept has since been applied by the International Decision Support Initiative 
(iDSI) to economic evaluations in global health13 and was recently extended by the second US 
Panel14.  
However, while these past guidelines include sections on costing, these sections focus primarily on 
reporting, and do not explicitly address the methods and processes behind cost estimation. Many 
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countries do not yet provide routine data on costs, so primary data collection and estimation is 
required. Furthermore, cost data are required for more purposes than economic evaluation. This 
Reference Case should be complementary to the other Reference Cases, providing additional 
specification for those analysts who need to collect primary cost data. 
The Reference Case presented here provides guidance on and encourages consistent adherence to 
core principles for evaluating intervention costs.  The Reference Case structure adopts a “comply or 
justify” approach, which allows the analyst to adapt to the specific requirements of the costing 
exercise, but introduces the condition that judgments about methods choices are made explicitly 
and transparently. The principles are not intended to methodologically restrict or exclude novel 
methods to improve or expand cost estimation. Where methods are unclear or lack consensus, this 
Reference Case presents reasonable options for the analyst to consider, highlighting the strengths 
and weaknesses of each. 
The Reference Case is designed to facilitate costing analyses, rather than adding onerous burdens on 
analysts. The Reference Case offers standards for the design, implementation, and reporting of cost 
estimates. It does not offer a comprehensive ‘how to’ guide, but we hope that the principles 
outlined here can inform the development of detailed costing manuals and tools, by our team and 
others. However, we do provide some tools, such as reporting tables, that can standardize and 
streamline the process of adopting the Reference Case principles.  
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REFERENCE CASE GUIDE 
For whom is the Reference Case intended?  
 
The Reference Case is intended for use by multiple constituencies, including policy makers, program 
managers and staff, health service managers and analysts who support them, working in national 
ministries, international donor and multilateral organizations, private foundations, research 
institutions, and non-governmental organizations. It is intended to provide an overview/reference 
document of costing methods that can be applied in different documents and tools to support 
costing, depending on the audience and purpose. It does not replace the need for these tools, such 
as intervention-specific costing manuals. The one ‘tool’ it does provide is reporting standards.  
For those who fund cost estimation, the Reference Case provides a minimum standard that can help 
funders design Terms of Reference (ToR), including specific reporting requirements. 
For those who use cost data, the Reference Case provides guidance that can be used to assess 
whether a cost estimate is ‘fit for purpose’. These users may be economic analysts, modelers, or 
financial experts in government and non-government organizations, who wish to use the data 
collected by others to conduct economic and financial analyses. These readers are also advised to 
focus on the introductory sections, and on the reporting matrix contained in Appendix 2 that 
provides quality indicators according to purpose.  
For those who produce cost data, all sections of the Reference Case should be of interest, as a 
background reading into the main principles and methods behind costing studies.  This is the primary 
target group for the Reference Case. However, the Reference Case does not provide a ‘how to’ 
manual for costing any specific health intervention; instead it provides the principles required for 
study design and methods development. The sections on methodological specifications provide 
detailed guidance to achieve best practice in cost estimation. The Reference Case can be used to 
design detailed tools and guidance for those leading the costing of specific services and 
interventions, but it does not include data collection or analysis tools. The GHCC website is expected 
to include selected examples of data collection and analysis tools that are ‘Reference Case 
compatible’ at https://ghcosting.org, in addition to both downloadable Word and HTML versions of 
the full Reference Case. 
 
Structure of the Reference Case 
 
In line with the IDSI Reference Case on economic evaluation, the technical content of the Reference 
Case (both costing and reporting) is presented by defining principles and methodological 
specifications. Principles provide a set of rules that are sufficiently broad to gain consensus and 
apply in multiple settings. While the application of principles may vary depending on the purpose of 
the costing, they should be universally applicable to any cost estimate.  
Principles provide the conceptual framework for more specific methodological standards, where 
they are possible to define as they are supported either by evidence or theory. Principles also 
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provide the basis for standardized cost reporting. Methodological specifications are a set of 
methods that enable the analyst to adhere to the principles. They may not be exhaustive, in that 
there may be other means to achieve the same principles. The methodological specifications 
presented here are a work in progress and will be further refined by the GHCC over the course of the 
project.  
The Reference Case includes a reporting standards checklist, aligned to the principles, to support 
generalizability of cost estimates across settings and diseases. The final section provides additional 
specifics around the application of the Reference Case for all tuberculosis (TB) interventions and 
services.  
 
The process of Reference Case development 
 
The approach to developing the Reference Case was based on previous work developing reporting 
guidelines15. These outline the following stages of standards development.  
 
Box 1 – Summary of the iDSI Reference Case guidance on cost 
 
Principle 
 
All differences between the intervention and the comparator in expected resource use and costs of 
delivery to the target population(s) should be incorporated into the evaluation.  
 
Methods 
 
Primacy should be placed on the transparency, reasonableness and reproducibility of cost estimates, so 
that different decision-makers can assess whether the results are generalizable to their jurisdictions.  
 
Overall costs of interventions (excluding costs that do not vary across alternatives) should be reported as a 
key component of cost-effectiveness.  
 
Where data are adequate, costs of resource inputs to deliver interventions and quantities of resources 
should be reported separately from their unit costs/prices. 
  
All resource items involved in the direct delivery of health interventions should be costed because there 
will always be opportunity costs. 
  
Economies of scale and scope may be important and should be incorporated when feasible. Caution 
should be applied when applying cost functions if these cannot be supported with reliable evidence.   
 
Costs should be estimated so that they reflect the resource use and unit costs/prices that are anticipated 
when interventions are rolled out in real health care settings.  
 
Costs should be reported in US dollars and in local currency. The date and source of the exchange rate 
used should be reported, as well as whether the exchange rate is unadjusted (real) or adjusted for 
purchasing power parity (PPP).  
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It is important to identify the need for a guideline and examine whether existing guidelines can be 
extended. While the purposes of costing go beyond economic evaluation alone, we decided to 
‘extend’ the Reference Case developed by iDSI on economic evaluation. We did this for two reasons.   
Firstly, costs are used for a range of purposes in addition to economic evaluation. Secondly, the 
Reference Case for economic evaluation does not provide guidance on cost data collection. While in 
some settings cost data used in economic evaluation are produced by routine systems, in many 
countries globally this is not the case, and analysts need to estimate costs using primary data 
collection. There is a wide range of tools available to do this, but no single comprehensive document 
that summarizes the ‘state of the art’ in the methods used to inform these costing tools. 
The next stage is to review the literature to confirm the gap and to identify current evidence on 
methods. We conducted a bibliometric review (forthcoming) of methodological literature on global 
health costing. We then organized a meeting identifying participants through our networks, but also 
identifying authors from the bibliometric review. We conducted a survey among participants on the 
need for a Reference Case and current methodological gaps prior to the meeting. 
The GHCC core team wrote the first draft of this Reference Case as an explanatory document. It was 
then circulated to a list of technical advisors and stakeholders for review. In November 2016, a 
meeting was held to discuss the Reference Case and receive feedback. During the meeting, a review 
of the current quality of cost estimates and a systematic review of the literature on costing 
methodology were presented. In the latter case, the review included both academic papers and 
current costing guidance for global health. The meeting did not use a formal method to reach 
consensus, but all participants were asked to comment on the principles and suggest amendments. 
All suggestions were considered. Small groups met to discuss methodological specifications. In this 
case, some of the suggestions were incorporated, but where there was no agreement on methods 
specified, further working groups were established and the guidance has been left open. The 
Reference Case was then sent for review to all meeting participants. A list of all who contributed is 
contained in Appendix 4, including those who provided detailed comments on earlier drafts of this 
document.  
A publication and communication strategy will be developed to accompany the Reference Case. 
Both producers and users of cost data will also pilot the recommended guidance described in the 
Reference Case during 2017. The Reference Case will be made available on the GHCC website and 
updated as methods are further refined and developed. 
Finally, it should be noted that several updates for the Reference Case have been identified and will 
be further developed later in 2017/2018. These topics were identified during the November 2016 
meeting by participants. These are:  
 
a) Sampling for cost estimation (principle 8) 
b) Methods guidance on ‘within country’ cost functions (principle 15) 
c) Methods guidance on how to identify the most important resource use to measure (principle 6) 
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The scope of the Reference Case 
 
The Reference Case on global health costing provides guidance on estimating costs using primary 
data collection. Routine program monitoring systems, such as hospital cost accounting systems that 
estimate expenditures on specific procedures or diagnoses, can often provide useful information for 
costing analyses.  As will be highlighted later in this document, such expenditure information may 
not be adequate for costing analyses. Where routine systems are used to estimate unit costs, the 
Reference Case can help assess the quality of the estimates produced, as the quality of routine 
systems can vary considerably16. The Reference Case can thus help determine whether additional 
data collection is required. 
Currently, this Reference Case focuses on the costs of providing services. These can include items 
paid for by clients/patients. However, we do not include methods to estimate access costs (which 
can include direct expenses such as transportation, and opportunity costs from time spent accessing 
and receiving services), nor do we address the measurement of productivity losses from the 
symptoms of illness and/or death.  
This Reference Case does not provide standards and methods for conducting secondary analyses, 
such as programmatic budgeting by individual organizations, investment cases required by certain 
funding organizations, or estimating global price tags for a specific health technology or package of 
interventions.  The results of costing analyses are, however, often useful inputs for these other types 
of analyses. 
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ESTIMATING THE COST OF HEALTH INTERVENTIONS: AN INTRODUCTION 
 
This Reference Case is intended to be used by both economists and non-economists. To assist, a 
glossary of terms related to cost estimation is included in Appendix 1. In some cases, economists 
use terminology in different ways. Where this is the case, we have described this and identified the 
way in which we have used the term in the Reference Case in the glossary. There are, however, 
some issues and concepts that are particularly important. We therefore highlight the concepts, 
definitions, and terminology that are most critical to understand when using the Reference Case. 
What is meant by costing?  
 
Throughout this document, we use the term “costing” as a short way to describe the estimation of 
cost of health interventions or services in a specific context (location, time period, population, and 
other details discussed in later sections).  However, there are several different types of costs, and 
these are described below.  
Economic and financial costs 
Firstly, it is important to be clear on the difference between ‘economic’ and ‘financial’ unit costs. 
The principles and methods specified in the Reference Case state that different types of costs are 
appropriate for different purposes, and it is essential that the type of cost is reported. 
Financial costs capture the resources that are ‘paid’ for. They are thus contingent on the extent to 
which payment is made for the resources used. In cases where resources are donated, they would 
not be included in financial costs. Thus, financial costs can be generalized only across settings with 
similar payment structures. Also, since all resources (even donated) are paid by someone, financial 
costing implies a specific payer perspective – i.e., the financial cost from the point of view of an 
identified person, program, or organization.  
Financial costs can reflect what is planned to be spent (financial costs for budgeting) or what has 
been spent. Financial costs, however, are also distinct from expenditures in how they represent 
monies that have been spent. In any one year, financial costs represent the annual cost of capital 
inputs “smoothed out” across the years of use of that input, in contrast to ‘lumpy’ expenditures that 
record cost at the year of purchase of the capital input.  
In some guidelines, the term fiscal cost is used. Fiscal cost is a specific term used to describe costs 
incurred by public institutions.  
Economic costs aim to capture opportunity costs. The opportunity cost of a health intervention is 
defined as the value of the highest-value alternative health intervention opportunity forgone. 
Economic cost therefore aims to capture the full value forgone of all resources used. In well-
functioning markets, the price of a resource reflects its opportunity costs. However, in reality prices 
may not reflect value, and in some cases no market price is available. For example, if in one setting 
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volunteer time is donated, the financial costs of this time may be low, but the economic costs of the 
labor would consider market salary rates for the same labora. 
What is meant by a ‘unit cost’?  
 
Unit cost refers to the average cost of an intervention, service or output.  The phrase ‘Unit cost’ is 
also sometimes used to describe the cost of a specific input, such as ‘cost per test kit’. For this 
Reference Case, the cost for a unit of a specific input or resource is referred as to the ‘cost of an 
input’ or ‘the price of an input’.  
There are many different types of health interventions, services or outputs.  Health service ‘outputs’ 
can differ from per person reached by a public health strategy, to per person on a course of 
treatment, and to delivering one consultation or diagnostic test. The term ‘unit cost’ can be used to 
define the average cost of any of these. However, to support comparability when standardizing unit 
costs, some further clarity is required for each intervention. Defining both the intervention and its 
outputs to be costed is complex, as there may be a range of hierarchical outputs, and therefore to 
provide clarity, we adopt the following terminology: 
  
Intervention 
‘unit’ cost  
Average cost of an intervention (or strategy) (e.g., unit cost per person or 
episode of expanding TB treatment, or costs of peer education per person 
reached) 
Direct service/ 
output ‘unit’ 
cost 
 
Average cost per health service output/service delivered. This can be per 
person or per specific output/service (e.g., outpatient visit, diagnostic test, 
inpatient bed-day). In some cases, this may be the same as the intervention 
cost, but in other cases multiple services may combine to produce an 
intervention 
 
Supporting 
service/output 
‘unit’ cost 
 
Average costs of supporting or ancillary services and outputs. This can be per 
output or per specific service (e.g., critical enablers) that support the delivery of 
health services (e.g., cost of information and education per person reached)  
 
Activity cost Cost for each action required to provide services (may also be expressed as a 
unit costs, e.g., per health worker trained, in some circumstances) 
 
Resource use 
(sometimes 
referred to as 
Q’s)  
The quantities of inputs/resources (labor, buildings, etc.) used to produce 
activities 
Input cost 
(sometimes 
referred to as 
P’s)b 
Value of an input/resource (e.g., wage rate or amount paid for a test kit, or 
shadow price) 
 
                                                             
a It should be noted that opportunity cost is not always presented in monetary terms, but also can be expressed for example as the 
amount of health foregone. 
b While costs refer to value, and price only the financial amount paid, in common usage those estimating and using costs refer to the Q’s 
and P’s of inputs that make up costs. 
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Not every costing will involve such complexity, and sometimes the analyst will need to concentrate 
on estimating the unit costs of services only or specific activities. However, it is important to note 
that ‘unit’ costs may be very different depending on whether they are reporting intervention, 
service- or activity-level costs, and thus present challenges for standardization and understanding for 
both users and producers of cost data. Appendix 3 demonstrates how these distinctions can be 
applied to standardize the reporting of unit costs of tuberculosis (TB) programs. Box 2 provides an 
example, and further examples related to TB are provided in Appendix 3.  
 
Box 2 – Example of ‘unit’ cost typology applied to TB treatment adherence 
The intervention includes an m-health approach, which has a cost, but also will increase the average 
length of TB treatment. Therefore, the intervention cost will include the additional ‘direct service’ 
unit costs of the increased treatment length, and the ‘support service’ cost of providing m-health 
follow-up for patients.   
The cost of TB treatment will include estimating the ‘unit’ cost for ‘services’ such as outpatient visits, 
the costs of inputs such as drugs regimens, and then multiplying them by the quantities utilized. 
Likewise, the cost of m-health may involve estimating the ‘activity’ costs of training health workers 
that can then be multiplied by the number of persons trained. The cost of the activity may be 
composed of the estimates of the quantities (Q’s) and values (P’s) of each of the resources used in 
the training.  
 
 
 
Unit costs and cost functions 
 
Unit (or average) costs represent the total cost of producing a service divided by a given level of unit 
of intervention, output or service. ‘Unit’ costs can be measured across a whole program or for a 
specific site. As intervention, service or output levels increase or decrease, average costs will change. 
Input costs Activity  costs Direct  and  ancillary  
service  ‘unit’ costs 
Intervention ‘unit’  
cost 
Cost per person  
treated 
Cost per person  
successfully  
treated 
Q*Cost per  
person  
receiving m - 
health  
intervention 
Unit costs  
per health  
worker  
trained 
Buildings 
Materials 
Personnel 
Unit cost of  
software  
development 
Q*Cost per  
outpatient  
visit 
Q*Cost per  
regimen 
Unit cost of  
drugs  
transportation  
per facility 
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Cost functions describe how cost is determined by input cost, the amount of resources used, and 
other factors that may modify these such as the scale of production, or other characteristics such as 
quality. Cost functions reflect underlying production functions that describe how the factors of 
production, or ‘inputs’, can be combined to produce services and interventions.  
An average cost function describes how unit (or average) costs vary as the level of 
intervention/service increases. Average cost functions exhibit different shapes. In some 
circumstances, average costs stay constant for all levels of service and intervention provision. 
However, average costs often vary (sometimes non-linearly) as level of provision of intervention/ 
service increases. In the short term (referred to as the short run), the amount of some inputs used 
stays constant, or ‘fixed’, as the level of service provision increases. The determination of which 
costs are fixed is highly contextual, as the ‘fixity’ of a cost reflects the characteristics of inputs, 
preferences and constraints faced by managers. For example, in some settings staff costs are fixed as 
they are governed by overall public employment regulations and limits, while in other settings 
managers at a local level may be able to vary their staffing numbers at short notice by employing 
temporary staff. In some cases, costs may also stay constant over different levels of service 
production as they are ‘indivisible’ – for example, where a hospital needs a minimal level of 
investment in a ward, such as for a laboratory with certain equipment, even to start providing 
services. In this case, whether one patient or a high number of patients are seen, a large proportion 
of cost will remain fixed.  
At low levels of production, fixed costs may be spread across a low number of services/outputs, and 
so the average cost is relatively high. As production increases, fixed costs are spread across more 
persons and average costs decrease.  
There are other reasons why an average cost curve of providers may slope downwards, which may 
still apply in the ‘long run’ where the quantities of all inputs can be changed by managers, and all 
inputs and costs are ‘variable’. In the long run, as volumes of services increase, a downward slope of 
the U-shape cost curve may also occur. Relatively large volumes of service provision may enable 
improved service organization and ‘learning by doing’ within providers, resulting in a more efficient 
input mix. However, at very high levels of service provision, the production process may become 
challenging. For example, large hospitals may have such a complex service mix that they become 
difficult to manage, and average costs may start to rise, corresponding to the rising part of the ‘U’. 
Whether this happens in practice will depend on the specific service and how the management of 
services is organized. 
Taking a national perspective, average costs may also change with the scale of population coverage. 
Initially programs may also benefit from decreasing unit costs as some costs, such as program 
management, are shared over increasing volumes of service provision. However, there may also be a 
level of volume at which average costs increase again, due to the complexity of large-scale program 
management. Larger programs may also have to deliver services through increasingly small 
providers (with higher costs than larger ones), as they reach more remote locations. Likewise, the 
average costs of supervision and drug supply may rise as programs aim to cover more difficult-to-
reach groups.   
Therefore, theoretically, many global health services and interventions are hypothesized to have a 
production process initially exhibiting ‘economies of scale’, where average costs decrease as sites 
and/or programs expand. At a certain level, average costs may also begin to increase or exhibit ‘dis-
economies of scale’. However, the empirical evidence to support arguments of ‘economies of scale’ 
in health services remains weak and varies by service. Therefore, while both this Reference Case and 
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the iDSI Reference Case recommend the use of cost functions where available, empirical validation is 
often required before deciding on a specific form of cost function. Where there is none, the use of a 
single unit cost is accepted for most costing purposes. Nevertheless, it is important that those who 
measure and report ‘unit costs’ understand that the cost they are observing may be only be a good 
estimate in the context of the scale that it is produced, and any inference drawn should reflect this. 
Moreover, if the cost is to be transferred to other settings, those reporting costs need to provide 
sufficient information on context, such as the levels of service production. For further explanation of 
the term economies of scale, please refer to the glossary.  
A second critical issue that determines ‘average costs’ is the way in which unit cost of a service varies 
dependent on the other services it is delivered with. ‘Economies of scope’ exist where providers 
deliver services more cheaply where multiple services are delivered jointly. This efficiency gain can 
be due to improved sharing of ‘indivisible costs’ such as overheads, or, as with economies of scale, 
through aspects like joint learning (sharing clinical teaching services and provision is an example of 
this).  As with ‘economies of scale’, while there is a strong intuitive case that the joint production of 
services may reduce the average cost of each service, empirical evidence of the extent of these gains 
for most global health interventions remains scarce.  
Even if no economies of scope are assumed, the joint production of global health services often 
presents substantial practical challenges as the allocation of joint costs to different services may be 
required. The allocation of costs is covered in the guidance below, but will always remain difficult. 
Even if economies of scope are ignored, it is essential that those who measure costs of services that 
are produced jointly understand that the unit cost being measured may only be a good estimate of a 
specific combination of services, and any inference drawn should reflect this limitation. Reporting 
the extent to which the service being costed is integrated or produced jointly is also important.   
At present, this Reference Case does not provide methods guidance on the estimation of cost 
functions, but the methods described in this Reference Case can be used to collect cost data in 
preparation for such analyses. Further guidance will be issued in this area in the next version of the 
Reference Case. Briefly, there are several methods to do this. Broadly there are econometric 
(statistical) methods and more mechanistic models. Statistical methods exploring economies of scale 
rely on collecting unit costs from a large sample of sites. Time-series data can be used, although 
rarely so in practice to date, and may better describe the short-run average cost curve (depending 
on the length of the time series). If services or outputs change over time, however, time-series data 
may be limited. Key issues in all cost function analyses are the functional form and how to 
incorporate aspects such as quality. Mechanistic methods rely on understanding the underlying 
production function, describing how different inputs are used and combining this with detailed cost 
data. It is anticipated that subsequent versions of the Reference Case will elaborate and make 
further recommendations on this topic. 
* * * * * 
In summary, unit costs are at least in part determined by the relationship between inputs and 
outputs, and may vary by both the level of output (or service provision) and the scope of service 
provision, both of which are likely to change over time. While in some cases the average cost 
function for a service or intervention can be characterized using a single unit cost value, in many 
cases it cannot. If average costs vary, costs at a single point in time, at a specific level of service 
provision, may have limited usefulness for planning new services and for many other programmatic 
uses of cost estimates. When referring to ‘unit cost’ estimation, this Reference Case aims to facilitate 
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the estimation and measurement of ‘single’ unit costs; however, the methods used may also assist 
in providing the data to estimate average cost functions. 
 
Incremental vs. marginal unit costs  
 
Average or unit costs can include all the costs involved in producing a service compared to doing 
nothing, or the additional cost required to add or expand a service. In economic terms, the marginal 
cost is the cost of producing one (or small amounts) of an additional unit of output as service levels 
increase. Marginal costs capture how additional costs change as service levels increase one unit at a 
time. Marginal costs are also not necessarily constant as levels of service provision and interventions 
increase. As production increases, the marginal costs of producing one extra output or service often 
decreases depending on economies of scale, but may, in theory, also increase.  
Incremental cost is the term used to describe the difference in cost between two or more 
interventions or programs, or to compare a change of scale or approach to an intervention to the 
current provision. Incremental costs are the correct costs to estimate for economic evaluations (see 
iDSI Reference Case)c that always compare interventions.   
While the terms marginal and incremental cost are sometimes used interchangeably, incremental 
cost is the broader term, and includes marginal cost. Both marginal and incremental (financial) costs 
will in part be dependent on the extent of fixed costs (in the short run). However, this is more 
complex in the case when estimating incremental (economic) costs for an economic evaluation. 
Here, any resource that has an opportunity cost (i.e., it can be used for another purpose) that is 
different between the intervention and any comparator, even if fixed, would be included. For 
example, if a new diagnostic requires more staff hours than the standard of care, these staff hours 
should be costed. Staff will have an opportunity cost that could have been used for another 
intervention, even if resource use is drawn from current staff downtime. For further discussion of 
this issue see principle 6. 
  
Terminology around costing methods 
 
Terminology to describe costing methods is currently used inconsistently in the literature, e.g., the 
use of ‘top-down’ vs ‘bottom-up’ costing, and of ‘gross’ vs ‘micro’ costing. These terms are 
sometimes used interchangeably, and in other cases are distinguished from one another.  
Micro-costing focuses on a granular accounting of inputs, whereas gross costing considers only 
aggregate costs. A micro-costing disaggregates the costs of a specific output into the specific items 
consumed, such as nurse time and consumable supplies. A gross costing approach simply estimates 
all relevant costs, typically from program expenditure data, and divides by the associated outputs 
such as patient episodes. Gross costing may also be done using tariffs and fees17.  
In contrast, ‘bottom-up’ or ‘top-down’ refers to the way in which each resource is allocated to the 
unit cost being estimated. ‘Top-down’ costing divides overall program cost or expenditures, often 
                                                             
c Some also propose that full costs should be used (http://www.who.int/choice/en/) 
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including those above the service level, by number of outputs to calculate unit cost, while bottom-up 
costing measures input quantities at the client or activity level. Gross costing is commonly done top-
down.  
Micro-costing usually has a bottom-up element, measuring both service and resource use directly at 
the patient level, but may allocate some resources using top-down methods (e.g., administrative 
overhead). A specific hybrid form of micro-costing is ‘activity-based costing’ or ‘time-based activity 
costing’. This is not consistently defined as ‘bottom-up’ or ‘top-down’ in the literature. In some 
cases, it describes a ‘top-down’ process using a set of rules that allocate overall expenditures firstly 
to activities and then to services18. In other reports, it is described as a bottom-up approach19, which 
assesses the actual amount of resources to produce each service, usually by identifying activities and 
the staff time spent, and allocating costs according to this staff time use. 
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REFERENCE CASE APPROACH – COSTING FOR PURPOSE 
 
What makes a ‘good’ cost estimate? 
 
Fundamentally, costing is an estimation process. Any Reference Case therefore needs to be rooted in 
the scientific principle of what defines ‘good estimates’. However, as with any estimate, the extent 
to which cost estimates need to meet any quality criteria depends on the intended purpose for the 
estimates, which can be complex to define.  
So, what is meant by a ‘good’ cost estimate? In statistical terms, the quality of an estimate can be 
defined along two dimensions: 
Accuracy – This reflects the extent of systematic bias in an estimate (how far the estimate is from 
the true value of the population average cost), often referred to as internal validity. For example, an 
average cost estimate that systematically excludes overhead cost is biased downwards. 
Precision – This reflects the narrowness of clustering of the measurement around the central 
estimate, such as the mean. For example, if a small sample is used to measure unit costs, then it may 
have a high margin of error. 
These concepts are illustrated in the figure below20. 
 
Clearly, greater precision and accuracy are both desirable. However, defining an agreed minimum 
level of precision and accuracy is problematic and relies on the purpose behind making the estimate. 
Unit costs may be used for a range of purposes from routine financial management to estimates of a 
‘global price tag’ to scale up global health interventions (see the first section in the Reference Case 
below). These diverse purposes may require different degrees of precision and accuracy for different 
levels of aggregation (e.g., total vs. component costs). Moreover, costing itself can be expensive. The 
‘cost of getting it wrong’ therefore needs to be weighed against the ‘cost of getting it right’.  
There are some formal analytical techniques, such as the ‘expected value of perfect information’, 
that can help those considering how much to invest in improved cost estimates for specific purposes 
such as economic evaluation21. However, these analyses are expensive and time consuming in 
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themselves, and are thus not widely applied. Given the wide range of purposes and the lack of 
formal approaches available, there remains no simple way to define ‘a universal minimum standard 
of precision and accuracy’ for cost estimation in global health.  
There are two other important characteristics of cost estimates that may be relevant for specific 
uses. The first US Panel stated that a core rationale for Reference Cases is to facilitate the 
comparison of the results of different studies, so that “each study contributes to a pool of 
information about the broad allocation of resources as well as to the specific questions it was 
designed to address”14. This aim is particularly important in global health costing, where resources to 
collect data are scarce. Thus, three other properties of cost estimation that the Reference Case aims 
to facilitate are:  
Generalizability – the extent to which the cost estimate can be directly applied to other 
programmatic settings (often referred to as external validity) 
Transferability – the extent to which the cost estimate (with adjustments) may be transferred to 
other programmatic settings 
Comparability – the extent to which the features (for example the perspective and the resources 
included) of one cost estimate are similar to one another 
Unlike precision and accuracy, achieving generalizability may not be universally desirable. In some 
situations, the benefits of arriving at an accurate and precise context-specific estimate (internal 
validity) may override the benefits of a less precise but more generalizable estimate (external 
validity). Comparability, narrowly defined as an identical estimation process, may also not always be 
desirable for the same reasons as generalizability. However, comparability is less problematic, if it 
reflects improved transparency that permits analysts to adjust estimates in order to compare. So in 
summary, while generalizability is desirable in most circumstances, as with precision and accuracy, it 
is hard to set minimum standards in this respect without examining the intended use of the cost 
estimate. Comparability may, however, be improved simply through improved reporting, without 
adverse consequences.  
In addition, any estimation method should be reliable. Ideally, if carried out by different people it 
should give consistent results. Likewise, if the estimate is carried out over time results should be 
consistent. Finally, there should be consistency if carried out across different health interventions, 
services or outputs.  
The focus of a Reference Case therefore is not to set specific minimum standards for each of these 
characteristics of a ‘good’ cost estimate, but instead to define the ‘best methodological practice’ to 
support a cost estimation process that is fit for purpose and efficient given the funding and data 
available. It concentrates on providing a framework for analysts to structure their choices around 
study design and methods, and to consider how their methods influence the quality of their 
estimates so they can make efficient choices given their resources available to conduct the cost 
estimation. In doing so, it aims to improve both the precision and the accuracy of estimate for the 
funding available.  
The Reference Case is more prescriptive, however, in terms of setting minimum reporting standards 
to improve the transparency of cost estimation. While it does not recommend specific methods to 
be used, it provides standardized ‘units’ and ‘results tables’, in addition to a methods checklist, to 
improve the comparability, transferability and generalizability of cost estimates going forward. 
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DEFINING THE PURPOSE OF COST ESTIMATION 
 
The starting point for the Reference Case is to define the different purposes for which cost estimates 
are used. Ideally, any cost estimate could be used for multiple purposes (accepting that some 
adjustments may need to be made). In principle, the use of high-quality cost data can result in the 
improved allocation of resources to global health strategies, interventions, and services that 
maximize health gain and financial risk protection. Improved cost data can also result in cost savings 
and efficiency improvements that ultimately can be used to fund additional health improvement-
related activities. Moreover, if cost data are used to inform the equity of financing (and costs) 
between different payers, then ultimately good cost data can be part of reducing any negative 
poverty impact associated with ill health.  
In practice, budgets for cost estimation projects are often set with a specific purpose in mind, and 
the methodological choices will be driven by that purpose. Each of these purposes may require 
different approaches to definition and measurement (e.g., the scope, frequency, and unit of the cost 
reported), and there may be different emphases in areas such as sampling. We have, therefore, 
indicated throughout the Reference Case where principles may apply differently depending on 
purpose. The starting point is to define the purposes. For simplicity, four ‘buckets’ of purposes are 
defined:  
1. Economic evaluation and/or priority setting 
 
This purpose is defined as the use of cost estimates in analytical approaches to assess allocative 
efficiency (see glossary) of investment and policy decisions. These include, for example, cost-
effectiveness analysis, cost-benefit analysis, health technology assessment, essential package 
definition, benefits package definition, etc. It may also include investment cases, linking closely to 
the estimation of resource requirements as below. 
Comparisons of the cost-effectiveness of alternative uses of resources are now recognized as a core 
piece of information in decisions around whether to invest in new technologies, or set priorities 
across different strategies and interventions. For example, cost data are often critical in shaping the 
design of health care benefit packages provided by governments or insurers and, as many low-
income countries move towards national insurance schemes, are needed to estimate 
reimbursement levels.  
2. Medium- and long-term financial planning and resource requirements estimation 
 
This purpose describes the use of cost estimates to predict expenditures in the medium (3 to 5 
years) and longer term. Examples include using costs to inform budget impact analyses, support 
medium-term expenditure frameworks, inform budgets for national strategic plans, develop 
financial plans for investment cases, and produce ‘global price tags’. These analyses both support 
national planning but can be used in both national and global fundraising efforts for increased 
investment in a specific global health area. For example, since 2009, the South African government 
has collected cost data to predict the medium- and long-term costs to the South African national 
public sector antiretroviral treatment (ART) program, which was then used to advocate for 
increasing funding for ARTs of funding.  
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3. Budgeting and price-setting 
 
Cost data may be of use to those planning both the incomes and expenditures of health providers 
(or funders). This purpose describes the use of costs to predict expenditures by specific budget 
holders and set prices for specific services. Budget settings would include annual program budgeting 
by managers for routine health services, or a specific provider, or could refer to an investment case 
for a specific project or a funding application. For some organizations, such as insurance companies 
or private providers, budgets involve planning incomes, and prices for specific goods and services for 
the coming year and costs are core element in this process.  
4. Technical efficiency analyses 
This purpose describes the use of costs to explore differences and drivers of technical efficiency (see 
glossary) between providers and/or modes of delivery (integrated services, platforms, level of 
decentralization, etc.) for health interventions or services, usually conducted through the 
comparison or analysis of costs over multiple sites, or by comparing estimate costs to benchmarks. 
Cost data from studies that help to estimate technical efficiency provide critical information for 
improving the value for money on the supply side, such as identifying the minimum efficient scale of 
operation, or providing insights into areas of efficient or inefficient practices. For example, WHO, 
UNICEF, and GAVI use unit cost data to identify and design efficient supply chain logistic systems in 
immunization. 
For each of these purposes, there may be different theoretical and practical reasons why a certain 
type of cost or methodological approach is preferred. For example, where countries are moving 
towards universal health coverage, the need to generate reimbursement rates and to understand 
the comparative value of new technologies (i.e., applying economic evaluation/and or priority 
setting) creates a demand for unit cost data that are comparable across diseases and health services, 
follow a standardized methodology, and reflect economic cost. 
In contrast, cost data for technical efficiency studies may need larger sample sizes, have a different 
perspective, and need additional information about cost determinants collected to enable analysis. 
For the purposes of financial planning and resource requirement estimates, financial costs are 
generally needed rather than economic costs, and disaggregation of prices and quantities in unit 
cost reporting is helpful; in the South Africa example above disaggregated estimates were used to 
estimate the impact of changes such as introducing task-shifting to lower staff cadres and opening 
the South African antiretroviral drug market to international competition. 
Where recommended methodological approaches differ by cost purpose, these differences are 
explained in the Reference Case and illustrated throughout using two examples of costing exercises. 
The first example is based on an economic evaluation of condom distribution using community 
health workers in India, the Avahan program. The second example is based on an exercise to help 
the South African Government to plan roll-out of the Xpert MTB/RIF diagnostic for tuberculosis. 
These are only two examples and should be interpreted as illustrations, rather than any prescription 
of methods. 
The Reference Case is composed of a total of 17 methodological principles across four main topics: 
(1) study design; (2) resource use measurement; (3) pricing and valuation; and (4) analyzing and 
presenting results. For each principle, we provide an explanation as to why it is important, and 
information on the methods specification below. 
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1. STUDY DESIGN 
 
Once the purpose has been determined, this section outlines the five principles and methodological 
specifications relevant for study design. The various steps/choices to be made when designing a cost 
estimation are outlined in the diagram below. A summary of the principles to be applied in each step 
is also provided in Table 1. Table 1 also includes guidance on how study design may be influenced by 
the purpose of study and the availability of data. A statement of each principle and its 
methodological specifications follows the summary table.  
Table 1– Study Design ‒ Statement of Principles and Guidance by Purpose 
 
Economic 
evaluation 
Financial 
planning 
Budgeting 
Efficiency 
analysis 
Study design     
      
1 The purpose, the population, and the intervention 
and service/output of the cost estimation should be 
defined. 
 
All All All All 
2 The perspective of the cost estimation should be 
defined. 
Societal or 
provider 
Provider or 
payerd 
Payer Provider 
3 The type of unit cost estimated should be defined in 
terms of economic versus financial, real world 
versus normative best practice and full versus 
incremental cost, and whether the cost is net of 
future cost savings. The type of cost should be 
justified relevant to purpose. 
 
 
Economic 
cost 
Incremental 
cost 
Real world 
Net of future 
cost savings 
Financial 
cost 
Real world 
or guideline 
Financial 
cost 
Real world 
or 
guideline 
Financial or 
economic 
cost 
Real world  
4 The ‘units’ in the unit costs for strategies, services, 
and interventions should be defined, relevant for the 
costing purpose, and generalizable. 
 
All All All All 
5 The time horizon should be clearly stated and of 
sufficient length to capture all costs relevant to 
intervention and purpose, and consideration should 
be given to disaggregating costs into separate time 
periods where they vary over time. 
 
To capture 
all costs 
Length of 
financial 
plan 
One 
budget 
cycle 
(usually 
one year) 
Minimum 
one year  
                                                             
d Payer can also be a provider, but is more narrow, so just the part of the organization that is responsible for the funds being planned or 
budgeted for. 
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METHODOLOGICAL PRINCIPLE 1 – DEFINING THE PURPOSE  
 
The principle  
 
The purpose, the population, and the intervention and/or service/output of the cost estimation 
should be defined. 
Why is defining the purpose and intervention important? 
 
As outlined in the introduction of the Reference Case, cost estimates may be used for multiple 
purposes, and the characteristics of a ‘sufficient estimate’ will vary accordingly. For example, an 
economic evaluation may require an incremental economic cost, while financial planning may 
require a financial cost from a specific payer’s perspective. If a cost estimate is used for the wrong 
purpose, or if its limitations are not described, it can be misleading. Therefore, it is important to be 
clear on the purpose for which the cost estimate is intended. 
The requirement that the population and intervention and/or service/outputs be clearly described 
complies with standard economic evaluation guidelines, such as the US Panel recommendations and 
the iDSI Reference Case14. This information is essential for costs to be used appropriately and 
generalized to other settings, and provides the basis for determining the methods used for 
measurement. 
 
Method specification  
 
The introduction of the Reference Case provides examples of purposes that may be used. These are: 
economic evaluation, efficiency analyses, financial planning, and budgeting. The purpose should also 
identify both the relevance for health practice and policy decisions and the intended user(s) of the 
cost estimate, if known. 
Ideally the intervention and/or service/output should be defined within context describing: 
 Main activities/technologies involved 
 Target population 
 Coverage level or phase (pilot, implementation, post scale-up) 
 Delivery mechanism (health system level/facility types/community/ownership /integration 
with other services where relevant) 
 Epidemiological context (incidence/prevalence of the illness being addressed) 
 
The comprehensive production process of an intervention and/or service/output (i.e., the activities, 
plus key technologies) should be outlined in the first instance, and if any parts of process are 
excluded (for example above service delivery activities) these exclusions should be clearly reported.  
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METHODOLOGICAL PRINCIPLE 2 – DEFINING PERSPECTIVE 
The principle  
 
The perspective of the cost estimation should be defined. 
Why is defining the perspective of the cost estimate important? 
 
Once a purpose and user of the cost estimate is defined, it is important to address the perspective of 
the estimation. The perspective describes which payers’ costs are included in the estimate. Some 
users, who make decisions on behalf of a population, may need to use a societal perspective that 
captures all costs incurred by an intervention, regardless of who pays the costs. For other analyses, a 
more limited perspective may be taken. For example, to set a budget, it may only be important to 
estimate the costs that fall on a specific payer.  
The requirement that the perspective should be described complies with standard economic 
evaluation guidelines, such as the US Panel14 recommendations and the iDSI Reference Case13. There 
are increasing calls for economic evaluations to adopt a societal perspective, including the recent 
recommendation by the Second US Panel to report two Reference Cases, one from a provider and 
one from a broader societal perspective22.  
Method specification  
 
Most textbooks in costing and economic evaluation categorize perspective into two types: societal 
and provider. However, in practice, these terms are used to describe a multitude of payers. For 
example, a provider perspective may include costs incurred by health service providers and non-
health service providers, and be limited to specific payers. A societal perspective may also include 
client costs to access a service, costs to the household, costs to community, and in some cases even 
costs to the macro-economy or other sectors. Where clients or patients pay for services, the costs of 
provision may include a partial societal perspective. Therefore, a simple category stating the 
perspective as societal or provider is insufficient to generalize or compare costs. It is therefore 
recommended that a ‘stopping rule’ be defined and made explicit. A ‘stopping rule’ defines and 
explains which costs are included, and how the line is drawn between inclusions and exclusions. 
The methodological specification is therefore to define perspective as societal or provider, but in 
addition to justifying and listing the groups/payers whose cost has been captured in the estimate. 
For a provider perspective, this should specify whether both health and non-health providers are 
included. For a societal perspective, this should specify whether it is cost to the client only, or more 
broadly to the household, community, or society.  
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METHODOLOGICAL PRINCIPLE 3 – DEFINING THE TYPE OF COST  
The principle  
 
The type of cost being estimated should be defined, in terms of economic versus financial, real 
world vs. guideline, incremental vs. full cost, and whether or not the cost is net of future savings. 
The type of cost should be justified relevant to purpose. 
Why is defining the type of cost estimate important? 
 
For different purposes, different types of costs are required. For example, economic evaluation 
requires an incremental economic cost to ensure opportunity cost is appropriately estimated13. 
Conversely technical efficiency analyses may be interested in examining the full cost, to identify any 
possible resource use that is inefficient. Different types of costs will require different measurement 
methods, and for reasons of measurement design and comparability, it is important to begin any 
cost estimation process with a clear definition of what cost is being estimated. 
Method specification  
 
There are four characteristics that must be defined. First is the distinction between economic and 
financial cost (see introductory text and glossary). Whether the cost is economic or financial will 
dictate which resources should be included and how they should be valued.  
The next issue is whether the aim is to estimate the cost of an intervention conducted according to 
‘normative best practice’, or whether the aim is to provide a cost estimate that reflects the costs of 
implementing an intervention in the ‘real world’ (which may include inefficiencies or exclude 
intervention components). Normative best practice may be described in guidelines, but guidelines 
may be out of date and expert consultation may be used. In most cases, this will also be a mixed 
picture, not a dichotomy, with some aspects of the ‘real world’ being included, but not all. For 
example, normative best practice may be defined as ideal norms, or have more realistic elements. 
The setting where costs are collected may be pivotal. For example, where costs are collected in 
research settings they may be gathered from clinical trials or more pragmatic settings. Costs for 
economic evaluation are often collected from clinical trial sites, where the cost may include activities 
to ensure adherence to a guideline, which may also contribute to the effect size used in the 
incremental cost-effectiveness ratio (ICER) estimation. In this case is important to be clear that the 
costs include activities to ensure guideline adherence. It is therefore necessary to provide more 
detail than simply stating whether the cost is real world or based on guidelines. Given the 
complexity involved, transparency around this issue is particularly important.  
It is also important to clarify whether the cost estimate is incremental to any comparator or a 
standard of care. The definition of incremental is outlined above in the introductory section. Further 
guidance on defining resources to be included in cost estimates is provided in methodological 
specification six below.  
Finally, many global health interventions are preventative, and therefore it is important to report 
whether costs are net of future cost savings for health providers and households or just the costs of 
the immediate intervention.  
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METHODOLOGICAL PRINCIPLE 4 – CLEAR DEFINITION OF ‘UNITS’ 
The principle  
 
The ‘units’ in the unit costs for strategies, services, and interventions should be defined, relevant for 
the costing purpose and generalizable.   
Why is using clearly defined and standardized units important? 
 
A critical challenge in transferring and synthesizing cost estimates in the past has been the lack of 
standardized ‘units’ costs for interventions, episodes of care, and service usee. This lack of 
standardization has created difficulty in assessing efficiency across settings, made past and existing 
efforts to conduct systematic reviews problematic, and impeded the creation of global datasets of 
costs that can be used to extrapolate costs to settings where data is currently absent. A key aim of 
this Reference Case is to address this gap by developing a standardized set of units for different 
disease and intervention areas. 
Method specification  
 
The introduction section above describes the categories of unit costs that may be defined 
(strategies, intervention and service units). As part of this Reference Case we also provide examples 
of standardized units for TB, based on the ‘units’ of strategies, services, and interventions that 
countries are reporting activity on globally, in Appendix 2. There is also guidance available in other 
areas, such as immunization, often developed in conjunction with global agencies working in specific 
areas.  These can be found on the GHCC website: https://ghcosting.org/  
In all cases these units should be reported, although in some circumstances it may be relevant to 
report additional units. For new interventions, or interventions with new components, other units 
may need to be developed beyond the standardized unit costs in this Reference Case. In some cases, 
the management information systems that report on the various ‘units’ will not align with the 
standard definitions; if this is the case, effort should be taken to collect the necessary additional data 
to adjust this reporting, or clearly explain any bias in terms of standardized reporting units. 
Finally, a critical issue to consider is the use of quality-adjusted ‘units’. This is particularly the case 
for purposes that are examining efficiency. Comparing costs of services that are of varying quality 
and thus different is misleading. To explore efficiency, analyses may therefore want to examine the 
factors that influence the cost of services reaching a similar quality. For example, the purpose of the 
costing may require that the cost per person completing treatment, rather than the cost per 
treatment month, is explored. In other cases, the analysis may also consider quality as a determinant 
of costs. Even if not formally analyses, in all cases, efficiency analyses should consider the quality of 
the output, in any inference made from these analyses.  
For other purposes, quality may be less critical to explore. For example, in cost-effectiveness 
analysis, the main metric is cost per outcome, and thus a decision may require also knowing the cost 
per quality adjusted output.  For financial planning and budgeting, ideally the quality of the service 
being budgeted for should be clearly defined as part of the intervention definition, and ‘unit’ costs 
then measured accordingly. 
                                                             
e Unit is referred to as output in some literature. 
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METHODOLOGICAL PRINCIPLE 5 – DETERMINING THE APPROPRIATE TIME 
HORIZON AND PERIODS 
The principle  
 
The time horizon should be explicit and of sufficient length to capture costs relevant to the purpose, 
and consideration should be given to disaggregating costs into separate time periods where they 
vary over time.  
 
Why is specifying time horizon and time periods important? 
 
Time horizon refers to the length of time of service provision or intervention implementation that 
the costs are being considered. While most unit costs are contained by the length of time it takes to 
provide the service or produce an output (for example, TB treatment is six months), there are other 
considerations depending on what costs are being estimated and the purpose of the analysis.  
In economic evaluation, it may be necessary to estimate a unit cost of an intervention per person 
(see box 2 above). In this case the time horizon may have to capture multiple services over time. The 
iDSI Reference Case for Economic Evaluation14 states that time horizon used in an economic 
evaluation needs to be carefully considered because any decision made at a point in time will have 
intervention benefits and resource use extending into the future. An economic evaluation should 
therefore use a time horizon that is long enough to capture all costs and effects relevant to the 
program or policy decision. Economic evaluation Reference Cases and guidance more generally 
emphasize that the time horizon should not be limited by the availability of empirical data. In some 
cases, however, it is not possible to measure future costs and economic evaluations may include 
imputation of data that are incomplete or missing23, with a number of analytical methods being 
available to address the specific issue of censored data24. Other uses of cost data may have more 
circumscribed time horizons related to financial planning periods.  
Finally, where estimating a unit cost for new services, it may make sense to disaggregate unit costs 
into different time periods. Costs may change during different phases of an intervention, and 
therefore an average unit cost over the entire intervention may have limited use for other analysts 
using cost data for specific phases of activities, particularly in financial planning. For example, costs 
may be different during the development of intervention, compared to implementation.   
Method specification  
 
For costs estimated for economic evaluations the time horizon should follow the methodological 
specifications in the iDSI Reference Case13. For other purposes, the time horizon should follow the 
planning cycle, (e.g., medium-term financial planning typically estimates costs for 3- to 5-year 
periods, while longer-term efforts to estimate resource needs to reach global targets may project 
costs for a 10- to 15-year period).   
For interventions that are being piloted or at the early stages of implementation, costs should be 
disaggregated into those in a ‘start-up’ phase and those in an ‘implementation’ phase, at a 
minimum, with the start-up phase being treated as a capital investment (see principle 12 below). 
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A start-up phase is defined as all costs incurred before the first service is delivered. For clinical 
services, like TB treatment or ART treatment, there may also be clinically related phases, such as 
intensive and continuation phases. Even within phases of treatment costs may vary, and it may be 
relevant to examine this in some circumstances. For example, hospital admission costs vary over the 
course of treatment (the first few days are often higher cost)25. For an economic evaluation 
comparing an intervention reducing length of stay, it may be necessary to capture this variation over 
days. 
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EXAMPLE OF THE APPLICATION OF STUDY DESIGN PRINCIPLES 
  
Example #1: 
Estimating the 
cost-
effectiveness 
of HIV 
prevention in 
India (Avahan) 
PRINCIPLE 2 - The 
perspective of the 
cost estimation 
should be stated 
and justified 
relevant to 
purpose. 
PRINCIPLE 3 - The type of cost 
estimated should be defined and 
justified relevant to purpose 
PRINCIPLE 4 - The 
‘units’ in the unit 
costs should be 
defined, relevant 
for the costing 
purpose, and 
generalizable. 
PRINCIPLE 5 - The 
time horizon 
should be of 
sufficient length to 
capture all costs 
relevant for 
purpose 
PRINCIPLE 1 - The 
purpose of the 
study, population, 
and intervention 
and/or service 
should be clearly 
defined. 
Economic 
evaluation 
Efficiency 
analysis 
Financial 
planning 
Budgeting 
Societal 
perspective 
Provider 
perspective 
Payer 
perspective 
Financial 
cost 
Economic 
cost 
Net of 
future costs 
Real world 
costs 
Guideline 
costs 
Incremental 
costs 
Full costs 
Intermediate 
outcomes 
Units of 
coverage 
Service use / 
outputs 
Capture all 
relevant costs 
Minimum one 
year 
Length of 
financial plan 
One budget 
cycle 
What perspective 
should I take? 
What type of cost should I 
estimate? 
What units should I 
cost? 
What time horizon 
should I use? 
What is the 
purpose of the 
study? 
Economic 
Evaluation - 
Cost-
effectiveness 
analysis of HIV 
prevention in 
India   
A societal 
perspective, 
and estimate all 
costs and 
benefits 
incurred by 
providers and 
by clients 
We estimate 
the economic 
cost 
We estimate a 
gross cost, 
due to the 
numbers of 
sites 
We estimate 
the real world 
costs of 
implementation  
We evaluate 
the 
incremental 
costs  
Costs per 
person 
reached (as 
community 
intervention) 
Four-year time 
frame to 
capture start-
up until full 
coverage 
Example #2: 
Planning scale-
up of Xpert for 
TB diagnosis in 
South Africa 
What perspective 
should I take? 
What type of cost should I 
estimate? 
What units should I 
cost? 
What time horizon 
should I use? 
What is the 
purpose of the 
study? 
Financial 
planning of the 
government of 
South Africa for 
roll-out of Xpert 
MTB/RIF across 
the country  
Cost data were 
collected from 
the payer 
perspective to 
help the 
National Health 
Laboratory 
Service (NHLS)  
Financial cost 
data was 
collected to 
reflect 
anticipated 
expenditures 
by the NHLS 
We estimate 
a micro-cost 
as there was 
good record-
keeping  
We estimate 
the full costs 
of Xpert as 
additional 
funding 
required 
varied by site 
Costs per test 
Costs were 
estimated for 
the length of 
financial plan, 
over two years 
We estimate 
the real 
world costs 
as best 
predictor of 
expenditures 
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2. RESOURCE USE MEASUREMENT 
 
The second part of the Reference Case focuses on resource use measurement, and the methods 
used to capture the quantities of resources used to provide an intervention and/or service/output. 
Five principles are defined, represented in Table 2 and in the figure at the end of the section.  
Table 2 
Service and resource use 
measurement  
Economic 
Evaluation 
Financial 
Planning 
Budgeting 
Efficiency  
analyses 
6 The scope of the inputs to 
include in the cost estimation 
should be defined and 
justified relevant to purpose. 
Where inputs are excluded 
for pragmatic reasons these 
should be reported. 
 
Incremental costs 
estimated between 
alternatives;  
analysis can 
address omissions 
or uncertainty 
Depending on 
purpose and 
timeframe 
All inputs for the 
relevant budget 
holder 
All inputs identified 
in the production 
process being 
analyzed 
7 The methods for estimating 
the quantities of inputs 
should be described, 
including methods, data 
sources and criteria for 
allocating shared costs, and 
the exclusion of research 
costs. 
 
All All All All 
8  The sampling frame, method 
and size should be 
determined by the precision 
demanded by the costing 
purpose and designed to 
minimize bias. 
 
All  
 
May require 
costs collected 
for different 
types of service 
providers 
Sampling frame 
for sites/patients 
funded by specific 
payer only 
May consider 
sample sizes that 
establish 
significance of 
specific cost 
determinants 
9 The selection of the data 
source and methods for 
estimating ‘units’ for unit 
costs should be described, 
with potential biases 
reported in the study 
limitations. 
 
All All All All 
10 Consideration should be 
given to the timing of data 
collection to minimize recall 
bias and, where relevant, the 
impact of seasonality and 
other differences over time. 
 
All All All All 
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METHODOLOGICAL PRINCIPLE 6 – SCOPE OF THE COSTING  
The principle  
 
The scope of the inputs to include in the cost estimation should be defined and justified and relevant 
to purpose. Where inputs are excluded for pragmatic reasons these should be explicitly reported. 
 
Why is defining the scope of the study important? 
 
Being transparent and justifying the scope of the cost estimate in terms of which inputs are included 
is critical for comparability and can allow others to determine bias. The risk of bias from excluding 
components of cost (e.g., program administration, a personnel category, or off-site support) leading 
to inappropriate conclusions from costing studies is well recognized and one of the core challenges 
in cost estimation26.  
Method specification  
 
The list of inputs to be included in the cost estimate will, in the first instance, be defined by purpose, 
perspective, timeframe and type of cost being estimated. For example, inputs such as volunteer time 
may be omitted where only financial costs are relevant (see principle 14 below). However, additional 
omissions may also occur as analysts balance the cost of data collection with potential bias from 
omitted inputs. While omission of items may be a practical necessity where expenditure or other 
records are not available on certain costs, it is essential that any deviation between the ideal scope 
according to purpose made, due to lack of data availability, is reported ‒ so that bias can be 
ascertained. 
 
There is a range of methodological guidance that can be used to comprehensively identify the inputs 
associated with an intervention and/or service/output. These commonly build from a description of 
the production process (principle 1 above). Both providers and patients can be involved, and there 
are formal methods that may be employed to map the full range of resource use associated with 
production27. In the first instance, analysts should use these tools to identify important inputs. In 
addition, in some cases, analysts may know of the cost structure from prior studies and can make 
informed judgments as to where primary data collection is most beneficial. Many studies also first 
pilot data collection instruments in a few sites to determine data availability and improve their 
understanding of the time and cost required to collect data on different inputs. All of these practices 
are recommended where feasiblef. 
Where economic costs are estimated, it is essential that all costs are considered, excluding those 
that do not change between interventions. Resources that are sunk or not currently used to full 
capacity should be considered as incurring opportunity costs, if they can be used for other services. 
For example, if a new diagnostic requires more staff time compared to an existing diagnostic, the 
cost of this additional staff time should be included, irrespective of whether current staff are fully 
utilized. The same applies for shared resources such as management information systems. If the 
capacity of the shared resource used by the new intervention is also flexible enough to use for other 
                                                             
f In the coming years, the Global Health Cost Consortium will seek to develop further guidance and tools to support analysts in the area of 
TB and HIV carry out this process.   
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purposes, then it has an opportunity cost. The extent of flexibility will be context and resource 
specific.   
There are also some resources that are commonly excluded on arbitrary grounds, and should not be. 
Recent reviews of studies28 where above service delivery costs have been included demonstrate 
that these costs can form a substantial part of intervention costs and yet are often not considered. 
“Above (delivery) site” activities include various support services provided by the central 
administration (e.g., Ministry of Heath) such as training, education and outreach, demand 
generation campaigns and central laboratory services. Most cost studies exclude these costs, or 
where they do include them, use inconsistent measurement methods. It is recommended that these 
costs should be considered in the same way as on-site costs, rather than arbitrarily omitted. Having 
said this, accessing data on above service costs can be a challenge. If a measurement process can’t 
be feasibly implemented then the omission should still be clearly stated, and any bias reported. 
A further area that warrants specific mention is the costs of supporting change. The costs of many 
interventions are estimated for rapid and substantial scale-up in low- and middle-income countries, 
and the associated costs of implementing change may also be important. Examples include the costs 
of changing guidance on drugs regimens, providing health systems strengthening to enable 
managers to reorganize services, or production of health workers to support scale-up of 
interventions. Some analysts may also choose to include the costs of intervention development, 
while some consider these as sunk costs.  These inputs should be included where relevant. 
Where costs are estimated for economic evaluation or long-term financial planning, there is 
currently no consensus on whether future costs should be included, nor is there strong evidence of 
their importance, so they may be omitted.  Nevertheless, analysts should state (if the costing 
includes future costs) whether unrelated costs are omitted as well as any methods for projecting 
future costs, and discuss any resulting bias in their projections or results. For analyses seeking to 
include future costs, it may be advisable to include both the health care costs directly related and 
unrelated to the specific condition being addressed by the intervention. For example, when working 
out the costs of a program that keeps those persons with TB or HIV alive, analysts may wish to 
consider the costs of treating any future illness29. 
Finally, when estimating incremental costs, determining the scope of the additional cost of the 
intervention to the comparator can be challenging30. There is no consensus methodological 
recommendation in this area. However, studies that compare different methods, for example 
statistical methods or the use of mechanistic cost models to estimate costs attributable to both the 
comparator and the intervention, find that the method chosen influences results31,32. In low- and 
middle-income settings, an important consideration is the extent to which the intervention and any 
comparators can be absorbed within existing under-capacity within the health system. If analysts 
adjust costs to consider spare capacity in the health system, they are therefore recommended to 
report any assumptions about existing capacity when describing the scope of ‘incremental’ cost. 
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METHODOLOGICAL PRINCIPLE 7 – MEASURING AND ALLOCATING RESOURCE 
USE 
The principle  
 
The methods for estimating the quantities of inputs should be described, including data sources, 
criteria for allocating shared costs, and exclusion of research costs. 
 
Why is describing the resource measurement methods important? 
 
The methods used to estimate the levels of inputs used in an intervention can bias estimates, and 
therefore should be reported. Broadly, analysts can select either a gross- or micro-costing approach, 
or a combination of both. Gross costing is defined as a process by which input use is estimated in 
total, and micro-costing where the analyst aims to estimate the usage of each input separately. In  
general, micro-costing tends to be more comprehensive and capture more input usage, with studies 
that compare micro- and gross costs finding that gross estimates tend to underestimate costs33. 
In the introductory material in this Reference Case it is highlighted that allocating costs between 
intervention is a challenge, and where the data is available it may be advisable to estimate total 
costs and derived incremental or marginal costs using econometric methods. However, in most 
circumstances, analysts need to design an allocation method for joint costs. The choice of using 
bottom-up or top-down allocation methods has also been shown to affect both the cost estimate 
and its applicability. While gross costing is done top-down (usually total costs divided by service unit 
levels), micro-costing may use both approaches to allocating resources. Bottom-up methods use 
approaches such as observation to estimate levels of input usage for a service, whereas top-down 
methods focus on allocating out the total amount of inputs used in facility, ward or clinic between 
services. Differences in cost estimates using bottom-up compared to top-down approaches are due 
both to measurement issues34 and to differences in the included inputs35. Top-down methods may 
capture some inputs where resource use cannot be observed due to demand or seasonal factors, for 
example, electricity. Top-down methods may also better capture inefficiency or down time and 
wastage. In comparison, bottom-up approaches allow for more understanding of individual service 
provision and may better characterize variation in practice36. They may also identify inputs that 
would be missed in a top-down allocation of costs, by improving the analysts’ understanding of the 
production process.  
In addition, there is increasing evidence that above service and overhead costs, which may have 
been conventionally allocated using simple ‘top-down’ techniques, may require more complex 
allocation approaches, given the substantial proportion of these costs for some global health 
interventions37. The choice of allocation methods may also be particularly important when costing 
hospital care38. One option to improve accuracy is to use techniques such as step-down methods39 or 
activity-based costing. These methods first assign costs to departments and/or activities; costs at the 
departmental and/or activity level are then assigned to services.  This step-down approach is 
recommended by some rather than using person-hours directly working on the service as typically 
done in micro-costing 40-42. In some cases, it may also be possible to use regression methods and 
matched comparisons to identify costs for a particular service, where total costs are available for 
sites (and patients) with and without the intervention43,44. 
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Human resources often make up the largest proportion of cost of global health interventions. Yet, 
health professionals, including community health workers, are often working in different services 
such as clinic and outreach settings. Measuring the human resources spent on an intervention is 
therefore one of the most important and challenging aspects of cost estimation and can 
substantially influence results.   
Finally, a further important issue is the allocation of costs between research settings and real-world 
interventions. Many cost estimates for novel interventions are conducted in trial or demonstration 
settings. There is an extensive literature highlighting the limitations of using cost estimates from 
these settings to model the costs of intervention implementation in the ‘real world’. While many 
cost estimates carefully remove research costs, the difference between ‘research’ and 
‘implementation’ costs can be hard to define. Those conducting cost estimates will need to make 
judgments/obtain information about how the intervention is likely to be implemented in the real 
world, for instance, whether or not an activity will be implemented, the frequency of activities, and 
the type of inputs – e.g., human resources – and include this in their assumptions. For example, 
activities such as ‘routine monitoring’ may change substantially if the intervention were scaled up.  
Moreover, it may be easy to remove items such as survey costs but harder to determine the costs of 
any adjustments made to the intervention design for research purposes. For example, trials 
commonly need to conduct additional activities to ensure protocol adherence or to reduce loss to 
follow up. Thus, the intervention cost during a trial may create a distorted estimate45. Even where 
these activities can be distinguished, research site selection may be biased46 and have different 
levels of efficiency than other sites. In some cases, costs can be adjusted to reflect real-world 
inefficiencies47. Finally, researchers can use input prices for inputs that will be used in real life rather 
than input prices in the trial. For instance, rather than use researcher/trial implementer salaries, 
they could use public sector health-worker salaries or average health-worker prices to reflect the 
likely costs on scale-up. 
It should be noted that although the removal of research costs is desirable for some purposes, there 
are exceptions. In the case of economic evaluation, the effect size observed (and then used in the 
incremental cost-effectiveness ratio) may in part be due to research-driven activities. If these costs 
were removed, then this would change and bias the incremental cost-effectiveness ratio. Whether 
or not analysts choose to include research costs in their estimates, clear disaggregation between 
research and non-research costs should be regarded as a minimum standard. 
 
Method specification  
 
While micro-costing is seen as a gold standard by some, we do not recommend it in this Reference 
Case as a minimum methodological specification. In many cases, the required level of disaggregation 
for levels of use by input may be unnecessarily onerous, or gross costs may be available from routine 
systems that have already been validated. Micro-costs are, however, particularly useful in situations 
where costs may need to be disaggregated and routine systems are weak. Moreover, the 
disaggregation of cost components allows for adaptation of costs to other settings and can assist the 
assessment of heterogeneity across patient groups48.  
In practice, many analysts use a mixed-methods approach. For example, a recent guideline for 
disease-specific costing, which was applied in Nigeria, combines micro-costing for some elements 
with more feasible gross costs for others49. Given the burden of data collection and the need to 
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capture all resource use, bottom-up measurement may not be required for all inputs. Those cost 
components that have the greatest impact on costs (labor and inpatient stay) may warrant more 
accurate allocation methods50. Analysts should therefore state the allocation method used for each 
input, including clearly describing if these are ‘top-down’ or ‘bottom-up’.  
In all cases, the methods/criteria used to allocate shared resources should reflect usage of each 
input and should be explicit. Where allocations have been made ‘top-down’, either to sites or within 
sites to services, or above service delivery or overhead costs have been allocated, the criteria used 
and the relevant data sources of the allocation factors should be explained. The bias inherent in any 
data source used to allocate input usage should aim to reduce bias. For example, recall by medical 
staff of time spent on intervention activities may be accurate when the intervention occurs in large 
regular blocks, such as every Tuesday morning. However, staff recall may be unreliable when the 
intervention activity is interspersed with other responsibilities in irregular ways. In such instances, an 
appropriate contemporaneous recording of activities using “time and motion” or work sampling 
methods may provide more precise data51,52.  There is mixed evidence as to whether this sort of 
continuous observation may also influence behavior, leading to biased measurement53,54.   
More specifically, careful attention should be paid to methods used to allocate human resource 
costs. Several methods are commonly employed to estimate time spent on a service or 
interventions. These include focus group discussions, interviews with providers or patients, 
examining patient records, time sheets, direct observation of practice, and work sampling. There is 
no ‘gold standard’ as each of these methods has biases. Several of the methods are subject to ‘self-
reporting’ or ‘observer’ bias that may result in more ‘desirable’ behavior. All methods may be 
subject to incompleteness. Approaches relying on patient records or reporting may not fully capture 
non-contact time (such as management and supervision costs), whereas approaches relying on self-
reporting may be overly burdensome and may be under-reported in busy periods.  
Where costs are collected as part of research into an intervention, research costs should be 
included, with the exception of when these costs could enhance the effectiveness of the 
intervention, and the costs are being estimate for an economic evaluation. Given the variety of 
methods, and the lack of a ‘gold standard’, the methodological specification for allocating costs, 
including human resource and research costs, focuses on reporting, and aims to ensure that biases 
are considered when designing the data collection method. A comprehensive description of 
methods, data sources, and allocation criteria by input should be reported for any cost estimate. 
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METHODOLOGICAL PRINCIPLE 8 – SAMPLING 
The principle  
 
The sampling frame, method, and size should be determined by the precision demanded by the 
costing purpose and designed to minimize bias. 
 
Why is a sampling strategy linked to purpose and consideration of bias important? 
 
Depending on the purpose of the cost estimation, the sampling frame may involve the selection of 
countries, geographical regions within countries, sites within regions, patients within sites, and 
different client groups. The purpose will also determine the appropriate sampling method and size. 
For example, some financial planning processes will require the collection of data from different site 
types. For economic evaluation, the aim is usually to compare the ‘intervention’ with the 
‘comparator’ and this will determine the method used.  
Due to logistical challenges and budget constraints, most cost estimates in low- and middle-income 
countries have been typically conducted on a small number of sites or locations (<10), though in 
recent years, larger studies have emerged, particularly in HIV. Where large studies have occurred, 
they have demonstrated a high variation of costs, suggesting that the common practice of estimating 
costs on a small sample may produce highly unrepresentative results55. However, even if a few sites 
are selected, explicit consideration (and transparency) of the sampling frame and method can help 
others apply cost estimates to other settings. 
 
Method specification  
 
Guidance on determining the optimal sampling approach for cost estimation is scarce, and therefore 
the methodological specification for this principle focuses on transparency and encouraging explicit 
consideration of each element the sampling approach, in line with recommended practice on 
sampling more generallyg.  
First, any sampling should begin with a sampling frame of sites or the population from which the 
sample is to be taken. In some cases, where a list of sites is unavailable, it is necessary to conduct an 
inventory of sites/facilities in order to come to a sampling frame. Even if random sampling or other 
methods cannot be used, the sampling frame can assist analysts in describing the bias in any 
eventual sample.  
The sampling strategy will depend highly on the purpose of costing; in some cases, obtaining 
representative data is not the priority or the sample may be pre-identified for political reasons.  
However, most costing efforts will aim to obtain cost data that is representative at a regional or 
national scale, in order to facilitate planning or decision-making.  Given the high costs and logistics of 
data collection, cost estimation frequently employs convenience sampling methods. However, these 
are likely to be biased, and techniques such as stratified sampling by facility size/type/ownership (or 
funding) and type of location (urban vs. rural) may offer practical alternatives to provide more 
                                                             
g The GHCC will be developing further guidance in the area of sampling for cost studies. 
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representative data. Sampling strategies should avoid convenience sampling wherever possible, 
aiming instead for a random or stratified approach. Even where convenience is an issue, techniques 
to avoid bias should be considered (for example, random sampling within convenient locations). In 
some cases, purposive or stratified sampling will be preferred (for example where costs are used for 
financial planning and scale up across different facility types), or maximum variation sampling where 
costs bounds are of interest. Finally, where cost data is being collected from individuals, it may be 
more pragmatic to sample clusters of individuals, rather than individuals. In all cases the sampling 
methods chosen should be clearly explained and justified. 
Cost data is generally highly skewed, and may therefore require a larger sample to obtain precise 
estimates.  However, due to the lack of clarity as to what level of precision is acceptable for specific 
purposes, it remains unclear whether or when large sample sizes should be considered standard 
practice, and difficult to recommend specific methods of sample size calculation. Having said this, in 
many cases it may be feasible and appropriate to formally determine sample sizes. In economic 
evaluation, methods have been developed to establish a threshold level of difference in cost-
effectiveness between the intervention and the comparator56,57. Studies on efficiency may use a 
sample size calculation based on establishing the significance of particular determinants of costs. 
Likewise, in TB programs, the sample size of national patient cost surveys supported by the World 
Health Organization was determined using an ‘acceptable’ level of precision around the extent of 
change over time of catastrophic costs. Guidance may also be drawn from the literature around 
sampling for multi-country studies that compare different sampling approaches (for example for 
cross country studies – whether few sites and more countries is more efficient than the converse58). 
As with the frame and sampling method, the approach to establishing the sample size should be 
described and justified. 
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METHODOLOGICAL PRINCIPLE 9 – MEASURING ‘UNITS’ OF OUTPUTS 
The principle  
 
The selection of the data source(s) and methods for estimating the ‘units’ for unit costs should be 
described and potential biases reported in the study limitations.    
 
Why careful selection of the source of data for estimating units is important 
 
Many unit cost studies need to estimate the unit costs from total expenditures, or they may need to 
measure quantity of the inputs being valued. Depending on the methods used, the approach may 
vary. For some studies, the top-down method may be used for some inputs. For example, an analyst 
may have the cost of overall expenditures from an X-ray department, and may need to divide by the 
total number of X-rays. In other instances, someone estimating the costs of treatment may need 
data on the number of visits or services accessed by patients.  
Much of the costing methods literature from high-income countries focuses on methods used to 
estimate service utilization. This need for methods guidance has arisen due to limits of using routine 
systems, particularly where patients are seeking care from multiple providers, including private 
providers. While some interventions are ‘one-stop’, in many areas they require multiple and 
complex service and technology use. In some cases, aggregate data (such as the number of patients 
completing TB treatment) may be available from routine systems, yet the numbers of visits/services 
utilization may not be, or where it is, it may be biased or incomplete. Of specific concern is where 
performance is either judged or incentivized based on routine reporting because these systems may 
be biased by over-reporting, leading to an underestimation of unit costs. 
 
Method specification  
 
It is hard to define a ‘gold standard approach’ for primary data collection that can be applied 
universally to health service utilization, community outreach, and general population-based 
behavior change campaigns. The literature from high-income countries comparing agreement in 
estimates from medical records, encounter logs, and patient reports may provide insights on an 
approach for low- and middle-income countries. Some have argued that medical record extraction is 
the gold standard, but in many low- and middle-income country settings these records may not be 
available or of suitable quality, or may be held by the patient. In other cases, service providers keep 
logbooks that may provide a useful source of data, however these data sources in different 
departments are not linked. Understanding patient flows and where events are documented is key 
in developing a data collection strategy that minimizes double counting and/or incompleteness of 
records. Others recommend patient interviews, the use of diaries or a resource-use log59. There is 
some evidence suggesting a high degree of convergence among methods60. But others point to the 
fact that even where there is agreement between records and patient self-reporting, there are 
different omissions (with patients reporting more service use for core providers such as GPs, but less 
service use for non-core providers such as pharmacies)61. Other studies have found that patients 
may also misclassify use62.  
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Moreover, different populations may exhibit different biases in terms of self-reported service use. 
One study found over-reporting amongst men and those with higher frequency of visits63. Elderly 
patients may under-report64. There are particular issues for the very sick and for children regarding 
the reliability of reporting by their guardians. Finally, responses may be different for different types 
of services. Reporting may be reliable for services like hospitalizations, but less so for general 
outpatient visits65. It may also be easier for patients to report visits, but not the use of medications 
and other care products66, particularly for chronic disease where longer-term recall is an issue. 
There are often trade-offs between accuracy and precision when selecting the appropriate method. 
Some propose regular phone surveys since they reach larger populations and hence can improve 
precision67, but these may have poorer reporting than face-to-face interviews. Where people are 
insured, claims data may be an option. Claims data (as with other routine reporting systems) can 
cover longer periods and larger samples but may cover fewer cost categories68. Simpler methods 
such as Delphi panel estimation using focus groups may also be considered where resources are too 
constrained for patient surveys69.  
In summary, there is no ‘gold standard’ approach, but it is important to consider characteristics of 
the sample population, their cognitive abilities, recall timeframe (see below), type of utilization, and 
frequency of use70. Comparing data from different sources may improve comprehensiveness of 
results. In some cases it may be useful to adopt formal analytical approaches to address biases 
caused by misreporting or incomplete data71. The methodological specification is therefore to report 
the source of data, report the approach used to sample or fill missing data and justify why the 
approach was selected given the potential for bias described above. Further research on this topic is 
needed to identify the best approach in LMIC settings. 
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METHODOLOGICAL PRINCIPLE 10 – TIMING OF DATA COLLECTION 
The principle  
 
Consideration should be given to the timing of data collection to minimize recall bias and, where 
relevant, the impact of seasonality and other differences over time. 
 
Why is considering the timing of data collection important? 
 
There are several issues to consider when deciding upon the timing of data collection. The first issue 
is whether data on resource use should be collected prospectively or retrospectively. Prospective 
data collection is often preferable, as it allows for direct observation of resource use and avoids 
issues associated with recall bias or missing/incomplete records. However, while prospective data 
collection may be more comprehensive and unbiased, there is a risk that the data collection 
methods may influence resource use72. Alternatively, retrospective data collection may be sufficient 
and more practical if relevant written records are available to track the way resources are allocated 
and any recall period is kept to a minimum. 
Where input and service use data are collected directly from clients or patients, several factors may 
also impact the quality of the resulting cost estimate; these include recall timeframe and utilization 
frequency70. Several studies have examined how accurately patients recall service use. Some suggest 
that a two- to three-month recall period can provide reliable estimates73, but point to differences 
amongst different types of health service use. In some cases, a shorter recall period does not provide 
adequate information on health service use, especially where events are infrequent74. For example, 
for studies concentrating on hospitalizations, the recall period may be longer75, but for community 
services, there may be under-reporting as the recall period is extended (four to eight months)76.    
In comparison, little is known about the accuracy of recall for health care workers, and this is likely 
to vary depending on characteristics of the time use (e.g., two half-day sessions per week vs. 
intermittent 10- to 15-minute blocks scattered throughout the work week).  
In addition to deciding whether resource use will be collected prospectively or retrospectively, it will 
therefore be important to consider the frequency of data collection over the course of the 
intervention being assessed. For many interventions, consideration should be given to the variation 
in costs across the project period as well as recall bias. For example, in addition to capturing costs 
during start-up vs. ongoing operations, other factors may affect the costs during the course of a 
year. In particular, seasonal fluctuations in service use may result in under- or over-estimation if 
costs are measured for less than one year. 
 
Method specification  
 
In general, analysts should clearly describe any limitations associated with the timing of data 
collection.  Analysts should consider whether retrospective versus prospective data collection is 
most appropriate, and whether the costs of the intervention and/or service/output will evolve over 
time. Where data is collected from patients/clients at different points in time, analysts should report 
whether this was cross sectional or a cohort. Where data is collected from interviews, consideration 
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should be given to recall period, and where recall periods are longer than three months, these 
should be justified. For interventions where provision or service use may exhibit seasonal variation, 
a minimum of one year’s period of cost measurement should be captured through either ongoing 
record-keeping or intermittent data collection efforts. In line with the principle on time horizon, for 
new programs, and especially demonstration projects or pilots, it will be important to time data 
collection to capture costs during both the start-up and implementation phases of the project, as 
these may differ substantially. In terms of frequency of data collection, it will be important to obtain 
information on resource use at the start of the project to capture start-up costs, followed by a field 
visit after the intervention has been running for three to six months to collect resource use for 
recurrent costs. Depending on seasonality and other factors affecting the supply and demand of 
services, subsequent visits may be needed to capture changes in service volume and resource use 
over the course of the project period. 
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EXAMPLE OF APPLICATION OF RESOURCE USE MEASUREMENT PRINCIPLES 
  
Example 
#1: 
Estimating 
the cost-
effective 
ness of HIV 
prevention 
in India 
(Avahan) 
 
PRINCIPLE 7 - The methods for 
estimating inputs should be 
stated, including data sources and 
criteria used for the allocation of 
shared costs  
PRINCIPLE 8 - The 
sampling strategy 
should be 
determined by the 
precision demanded 
by the costing 
purpose and 
designed to 
minimize bias. 
  
 
PRINCIPLE 10 - 
Consideration 
should be given to 
the timing of data 
collection. 
PRINCIPLE 9 The 
selection of the 
data source for 
estimating service 
use should be 
described, with 
potential biases 
reported in the 
study limitations 
PRINCIPLE 6 - The 
scope of the inputs 
to include in the 
cost estimation 
should be defined 
and justified  
Above-site cost 
Supporting 
change cost 
Research costs 
Unrelated 
costs 
Top-down 
Bottom-up 
Time sheets 
Overhead 
Research 
Work sampling 
Sample size 
Cohort or cross 
sectional 
Prospective or 
retrospective 
Data sources 
Recall 
Sampling 
frame  
What methods are taken to 
estimate resource use? 
What is the 
sampling strategy? 
How is service 
estimated? 
When was data 
collected? 
What is the scope 
of inputs included? 
Above service 
delivery costs, 
including 
program costs, 
all change costs 
Top down 
Timesheets 
Interviews to 
allocate 
overhead costs 
Management 
information 
system 
Sites with 
missing data 
excluded 
All sites 
Retrospective 
Example 
#2: 
Planning 
scale-up of 
XPERT for 
TB 
diagnosis in 
South 
Africa 
What methods are taken to 
estimate resource use? 
What is the 
sampling strategy? 
How is service use 
estimated? 
 
When was data 
collected? 
What is the scope 
of activities and 
inputs included? 
Service costs, 
Cost of 
supporting 
change 
Bottom up 
 Observation 
Interviews to 
allocate 
overhead costs 
Laboratory 
information 
systems 
Two-month 
recall 
Convenience 
sample 
Direct observation 
Missing data 
Sampling 
method 
 
No 
sampling 
127 sites 
Sampling frame is 
the sites in the 
clinical trial 
10 sites sampled 
One-year 
recall 
Cohort of 
providers 
Service use 
combining 
case note 
extractions 
with lab. 
records 
Retrospective 
Cross-
sectional 
Research costs 
excluded 
 
No unrelated 
costs 
 
Research costs 
excluded 
 
No unrelated 
costs 
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3. PRICING AND VALUATION 
 
The third part of the Reference Case focuses on pricing and valuation. Four principles are defined, 
represented in Table 3 and in the figure at the end of the section.  
Table 3 - Statement of Principles 
 Economic 
evaluation 
Financial 
planning 
Budgeting Efficiency 
analysis 
Valuation and pricing     
 
11 
 
The sources for price data should reflect the price 
relevant to purpose and be described for each 
input in a way that allows for adjustment across 
settings.  
 
 
Replacement 
prices; 
May wish to 
examine 
different 
future 
purchase 
prices for new 
technologies 
dependent on 
volume 
 
 
Future 
purchase 
prices 
 
Future 
purchase 
prices 
 
Prices paid 
12 Capital costs should be appropriately amortized 
or depreciated to reflect the expected life of 
capital inputs 
 
Amortization 
(Annuitization) 
Depreciation Depreciation Depreciation 
13 Where relevant an appropriate discount rate, 
inflation, and currency conversion rates should 
be used and clearly stated. 
 
3% discount 
should be used 
as well as 
local rates; 
No discount No discount No discount 
14 The use and source of shadow prices, for goods 
where no market price exists, and for the 
opportunity cost of time should be reported. 
Shadow prices 
should be 
applied to 
reflect full 
opportunity 
cost 
NA NA NA 
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METHODOLOGICAL PRINCIPLE 11 – SOURCES OF PRICE DATA 
The principle  
 
Sources of price data should reflect the price relevant to the purpose of the costing and be described 
in a way that allows for adjustment across settings.  
 
Why is transparency about the sources of price data important?  
 
Providing information on prices (including sources and methods used for salaries and wages) is a 
central aspect of transparency, and enables costs to be adjusted across settings with different prices. 
Different prices may be appropriate for different purposes. For example, financial planning and 
budgeting may need to estimate future costs, so contacting manufacturers of key technologies may 
be appropriate rather than assuming today’s prices will hold as volumes increase. There may be 
purchasing arrangements, which means that the prices of specific brands should be used. Efficiency 
analyses will need to examine the prices paid, and purchasing records may be a good source in this 
case. Economic evaluations may need to capture replacement prices in order to best capture current 
opportunity cost.  
 
Method specification  
 
The source of price data should reflect the purpose of the cost estimation.  
In some cases, some adjustments may need to be made from the price given in the original data 
source. For example, for wage and salary costs, adjustments may need to be made to ensure all 
benefits and remuneration are included and that gross price is captured. For example, efforts may 
need to be made to capture all the monetized benefits that public servants receive when pricing 
human resources. In the case of drugs and supplies, it may be appropriate to mark up prices by 
transportation costs.  
To enable the transfer of costs across settings, it is also important to distinguish local from 
international price sources, and between tradable and non-tradable inputs. Non-tradable inputs will 
always have local prices. Tradable goods may have both a local price and a price listed on global 
websites, etc. Wages are an example of “non-tradable” inputs; pharmaceuticals and lab testing 
equipment are often “tradable” inputs. Defining inputs as tradable and non-tradable and listing their 
price source is required to transfer costs across settings and to convert costs, where relevant, to 
international dollars. 
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METHODOLOGICAL PRINCIPLE 12 – VALUING CAPITAL INPUTS 
The principle  
 
Capital costs should be appropriately annuitized or depreciated to reflect the opportunity cost of 
capital inputs over the timeframe relevant to the decision problem.  
 
Why is transparency around valuing capital inputs important? 
 
The definition of a capital cost is any input with a useful life of more than one year, and can include 
non-equipment inputs such as training and bed linen. Start-up costs can also be considered as capital 
costs, given that their usefulness is typically longer than one year.  
Capital costs potentially have two components: depreciation (the reduction in the value of the asset 
over time due to wear and tear) and opportunity costs. The opportunity costs of capital reflect the 
lost opportunity to invest in another area. Even if an item of capital has been purchased some years 
ago, it can always be resold and still has an opportunity cost. Economic cost methods aim to capture 
this opportunity cost, whereas financial costs will only capture depreciation. Depending on the 
proportion of capital costs to total costs, differences in the method used to spread the cost over 
years can substantially impact unit costs77. 
 
Method specification  
 
Capital costs should be valued according to the type of cost ‒ ‘economic’ or ‘financial’ ‒ being 
estimated. Financial cost estimates should use straight-line depreciation (simply dividing the total 
cost by the years of useful life) and economic costs should use an amortization (sometime referred 
to as annualization) factor that adjusts the years of life for opportunity cost. It does this adjustment 
using a discount rate. As stated below in Principle 13, a 3% rate should be used in all cases to allow 
for international comparisons to be made. If local rates are available these should always be used in 
addition to the 3% rate. Standard tables are available to determine this adjustment78. 
The determination of the useful life of capital can also be problematic where the setting 
characteristics, such as the availability of repair and maintenance infrastructure, may influence the 
length of potential use. This is also the case for novel technologies where useful life has not yet been 
observed. It is therefore important to report useful life years used, even if assumption based, so that 
costs can be generalized and adapted to other settings and sensitivity analyses can be conducted.  
In summary, the method of depreciation and capturing opportunity cost, the discount rate, and the 
useful life (length and data sources) should be reported for each major capital input category and 
for new capital technologies by input.  
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METHODOLOGICAL PRINCIPLE 13 – DISCOUNT, INFLATION AND 
CONVERSION RATES 
The principle  
 
Where relevant, appropriate discount rate, inflation, and currency conversion rate should be used 
to adjust costs over setting and time. 
 
Why is transparency around price adjustments important? 
 
As above in principle 11, transparency around all adjustments to prices is essential; therefore, any 
adjustments made to adapt costs across setting and time need to be reported. The iDSI Reference 
Case for economic evaluation13 also states that when projecting costs into the future, costs need to 
be discounted to reflect their value at the time the decision is being made.  
 
Method specification  
 
In line with the iDSI Reference Case, a 3% annual and the local discount rate for costs should be used 
as a minimum specification. Additional analysis exploring differing discount rates appropriate to the 
decision problem can also be used, depending on the purpose and end user. In many cases an 
analysis that reflects the discount rate using the rate at which the national government can borrow 
funds on the international market (i.e., the rate used by the Treasury) may be preferable as the 
primary estimate for national level users. In this case, an adjustment for inflation may need to be 
made to reflect the real rate of return. 
To enhance generalizability of a cost estimate as stated above, we recommend at a minimum to 
present costs in local and US dollars, specifying the currency year. In some cases, it may also be 
advisable to present results in international dollars. International dollars, using a purchasing power 
parity conversion, remove some of the distortions and fluctuations inherent in currency markets and 
may better represent ‘economic’ value. However, for purposes such as financial planning, exchange 
rates are likely to be better estimates of price to be paid. In most cases, it may be necessary to also 
present costs in local currency. Where costs are reported over a time period, the mean exchange/ 
conversion rate over that year or time period should be used. The source of the exchange rate 
should be specified. 
Where prices need to be adjusted across time, gross domestic product (GDP) deflators or the 
Consumer Price Index (CPI) should be used for local goods (GDP deflators measure inflation in locally 
produced goods, rather than locally consumed goods). However, for inputs that are tradable, such as 
global health commodities (e.g., testing machines and anti-viral drugs), GDP deflators or the CPI do 
not capture price changes. Many global health commodities demonstrate decreasing prices over 
time. For these tradable goods, where feasible, commodity-specific price changes should be used. 
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There is a specific issue when adjusting costs over time and currency as to whether one first converts 
the local currency to U.S. dollars and then inflates, or vice versa, as this may make a substantial 
difference to the estimates. For non-tradable local goods, it is preferable to inflate local currency 
and then convert. Conversely, for tradable and often globally purchased and priced goods (where 
current prices are not available), it is preferable to inflate using the US dollar GDP deflator and then 
convert into local currency.  
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METHODOLOGICAL PRINCIPLE 14 – USING SHADOW PRICES 
The principle  
 
The use and source of shadow prices to value inputs without a market price and the opportunity 
cost of time should be reported. 
 
Why is shadowing pricing important?  
 
Shadow prices have two related meaningsh. The one used here describes the assignment of a price 
where there is no market price paid for an input. One common area in global health costing 
requiring shadow pricing is for donated inputs, such as contraceptives, and volunteer time. Likewise, 
some inputs may be partially subsidized. For example, ISPOR guidelines state the drugs costs should 
include rebates and other drug price reductions79.  Regulatory requirements may also distort drugs 
costs80.  
For economic evaluation and other ‘economic’ rather than financial analyses, shadow prices are 
important as they can help capture opportunity cost. In most instances, the use of shadow prices will 
involve adjusting the price paid to reflect the opportunity forgone, often using a hypothetical market 
price.  
Likewise, there is an opportunity cost of family and community members’ time for the provision of 
health care. In some cases, this may be forgone leisure time, but time may also be forgone for other 
productive activities such as housework, where there is no formal wage. For these costs, there are 
several approaches to estimating the value of lost productivity with different theoretical and 
conceptual bases (e.g., human capital vs. friction costing81). Depending on the approach, the value 
applied can use occupational and gender-specific wages, or equal replacement wages. Each of these 
can produce quite different estimates, and therefore the methods used should be made 
transparent82.  In many LMICs the extent of informal sector employment and reporting of official 
wage rates can mean that appropriate estimates may be unavailable. In some cases, the method of 
valuation includes normative aims, such as ensuring the equal valuation of time between men and 
women within a household.  
 
Method specification  
 
For economic costs, the prices of donated or subsidized goods need to be adjusted to reflect 
opportunity (economic) cost, often using market prices paid by other consumers, or if tradable 
goods international prices can be used. The valuation of donated or subsidized goods should, where 
practical, be based on an average of multiple estimates of local market prices; purchase price paid by 
the donator; or if neither of these approaches was used, an alternative approach should be 
described. 
                                                             
h The term shadow price can also be used in constrained optimization, where the shadow price is the increase in the numerical value of the 
optimal solution as a constraint is relaxed. For example, as a constrained health sector budget increases, the shadow price of the 
constrained budget is the number of the additional (optimized) health outcomes to be gained by the budget increase.  
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Where shadow pricing is used for the valuation of inputs with no market prices (volunteer time, 
household time), goods and volunteer time should be valued at a minimum according to a proxy or 
hypothesized market value (e.g., local economy/domestic service wage rates), and the method 
should be described. Valuation may also include normative adjustments, and these too should be 
explicated.  
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EXAMPLE OF THE APPLICATION OF PRICING AND VALUATION PRINCIPLES 
 
Example #1: 
Estimating 
the cost-
effectivenes
s of HIV 
prevention 
in India 
(Avahan) 
 
PRINCIPLE 12 - Capital 
costs should be 
appropriately 
amortized or 
depreciated to reflect 
the expected life of 
capital inputs 
PRINCIPLE 13 - Where relevant an 
appropriate discount rate, inflation and 
currency conversion rates should be used, 
and clearly stated. 
PRINCIPLE 14 - The use 
and source of shadow 
prices, for goods and 
for the opportunity 
cost of time, should be 
reported.  
  
PRINCIPLE 11 - The 
sources for price data 
should be listed by 
input, and clear 
delineation should be 
made between local 
and international price 
data sources, and 
tradable and non-
tradable goods 
Local price data 
sources 
International price 
data sources 
Tradable goods 
Non-tradable 
goods  
Expected life 
years 
Depreciation 
Currency 
conversion rate 
source 
3% discount rate 
Currency and 
year 
Inflation rate 
source 
Volunteer time 
Adjustments to 
input prices 
How are capital costs 
annuitized? 
How are discount rates, inflation, and 
currency conversion handled? 
How are shadow prices 
estimated? 
What is the source for 
price data? 
3% amortization 
3% discount 
US$ 2014 
Minimum wage 
Adjustment to 
condom prices as 
subsidized 
GDP deflator 
Example #1: 
Planning 
scale-up of 
XPERT for 
TB diagnosis 
in South 
Africa 
How are capital costs 
amortized? 
How are discount rates, inflation, and 
currency conversion handled? 
How are shadow prices 
estimated? 
What is the source for 
price data? 
Ministry of Health Straight line 
depreciation 
No discount 
US$ 2011 
No adjustments Mean exchange 
rate US: ZAR 2011 
Expenditure 
records and 
purchase 
orders 
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4. ANALYZING AND PRESENTING RESULTS 
 
The fourth part of the Reference Case focuses on analyzing and presenting results. Three principles 
are defined, represented in Table 4 and in the figure at the end of the section.  
Table 4 - Statement of Principles 
 Economic 
evaluation 
Financial 
planning 
Budgeting Efficiency 
analysis 
Presenting results     
 
15 
 
Variation in the cost of the intervention 
by site size/organization, sub-
populations, or by other drivers of 
heterogeneity should be explored and 
reported. 
 
 
Methods 
may need to 
consider 
correlation 
with 
effectiveness 
 
NA 
 
NA 
 
Descriptive 
or 
statistical  
analysis to 
understand 
drivers of 
costs 
 
16  The uncertainty associated with cost 
estimates should be appropriately 
characterized. 
 
Simple and 
probabilistic 
sensitivity 
analyses 
 
Yes, sensitivity 
analyses to 
inform 
contingencies  
Yes, 
sensitivity 
analyses to 
inform 
contingencies 
Yes, 
sensitivity 
analyses 
and 
possibly 
statistical 
analyses 
 
17  Cost estimates should be communicated 
clearly and transparently to enable 
decision-maker(s) to interpret and use 
the results.  
 
All All All  All 
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METHODOLOGICAL PRINCIPLE 15 – EXPLORING COST FUNCTIONS AND 
HETEROGENEITY 
 
The principle  
 
Variation in the cost of the intervention by site size/organization, sub-populations, or by other 
drivers of heterogeneity should be explored and reported. 
 
Why is understanding heterogeneity within cost estimates important? 
 
As the introduction section of the Reference Case explains, unit costs are rarely constant over scale 
(or other organizational characteristics), and in many cases, may not be similar for different sub-
groups of populations. Hence, it is important to explore differences in cost by site and population 
group. Exploration and reporting of these heterogeneities will also assist in extrapolating costs from 
the study to other settings and scales of delivery.   
With respect to population group, in some cases presenting aggregate unit costs may be highly 
misleading if others apply the unit costs to populations with different characteristics. For example, 
applying an average cost of treatment for drug-susceptible (DS) TB and multi-drug-resistant (MDR-
TB) patients would only be relevant to settings with approximately the same prevalence of TB and 
MDR-TB. In this case, the unit cost of treatment for each different patient group would be more 
useful. In addition, it will be important to consider underlying conditions or co-morbidities that may 
impact health-care costs for other diseases83.  
 
Method specification  
 
While it is preferable to examine average cost functions rather than a single ‘unit cost’, the amount 
of data needed to do this is substantial. In the main, the statistical requirements to estimate 
functions require relatively large sample sizes (number of facilities or other sample unit >30), which 
may be beyond the funding availablei. We therefore do not recommend this as a minimum standard. 
Nevertheless, we recommend the reporting of unit costs by site (e.g., facilities or other units of 
observation) together with a set of site characteristics (see minimum reporting standard and 
example tables in Appendices 2 and 4). Mean unit cost estimates can also be disaggregated by other 
categories that may drive heterogeneity, including service delivery platforms or type of setting (e.g., 
rural and urban) and quality of care. Heterogeneity should be explored in sub-groups of the 
population where the differences are likely to have an important influence on costs.  
Categorical or sub-group formation should be informed by both the characteristics of different 
populations and determinants that may influence unit costs such as geographic location. Where 
feasible the identification of these characteristics can be aided with formal statistical testing of 
differences. Where differences are found, unit costs should be presented by sub-group and a 
                                                             
i The GHCC will be further exploring methods to estimate ‘within country’ cost functions, and further guidance will follow. 
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weighted average constructed for the whole population. It should also be noted that the 
presentation of unit costs by sub-groups may also be desirable from a programmatic perspective 
(e.g., where programs may be interested in a stigmatized or high-risk population).  
Where sample sizes are larger, econometric approaches to characterizing cost functions can be used. 
It is beyond the scope of the Reference Case to provide guidance on these methods at this time.  
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METHODOLOGICAL PRINCIPLE 16 – DEALING WITH UNCERTAINTY 
 
The principle  
 
The uncertainty associated with cost estimates should be appropriately characterized. 
 
Why is characterizing uncertainty important? 
 
Since many global health-costing studies have a handful of sites (or other unit of observation), there 
is often no formal method used to characterize the precision of the estimate. Even measures of 
dispersion are rarely presented. However, there is likely to be considerable uncertainty in any cost 
estimate due to both bias and lack of precision. It may be misleading if the uncertainty is not fully 
characterized, and the user is not made aware of the possible space between the estimate and 
reality. Further, exploring the implications/sensitivity of the cost to any assumptions or exclusions 
made can enhance generalizability of results. 
 
Method specification  
 
The uncertainty of any cost estimate should be fully characterized. For studies with multiple sites (or 
other units of observation), this should at a minimum include an assessment of precision (e.g., 
confidence intervals, or percentiles). Care should be taken to examine whether the observations are 
normally distributed, and where they are not, to use the appropriate statistical techniques. In 
addition, where relevant, basic or more complex sensitivity analyses should be applied in standard 
ways (see economic evaluation textbooks). 
It is particularly important to characterize the bias in the estimate by referring to: 
 Sampling that may reflect higher- or lower-cost sites or populations disproportionately 
 Completeness – what elements of costs are missing (inputs, service use, providers) 
 Possible under- or over-reporting of elements such as service and time use due to the data 
collection methods or program features 
 Distortions or incompleteness in the prices of inputs. 
 
While it may not always be feasible to quantify bias, the characteristics and direction of any bias 
should be reported in the study limitations.  
Finally, any discussion section should include recommendations in terms of the generalizability of 
estimates to other settings and scales. For example, it may be important to highlight how service 
delivery may differ between the studied program (often a demonstration or pilot) and scaled-up 
operation (which may achieve efficiencies in staffing or different input prices). 
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METHODOLOGICAL PRINCIPLE 17 – TRANSPARENCY 
The principle  
 
Cost estimates, including the methods used, should be communicated clearly and transparently to 
enable decision-maker(s) to interpret and use the results.  
 
Why is transparency important? 
 
Cost estimates may be used for multiple purposes, for policy development and broader economic 
analysis. The characteristics of a ‘good estimate’ will vary depending on its purpose. If a cost 
estimate is used for the wrong purpose, or if its limitations are not described, it can be misleading. 
Moreover, the most methodologically robust costing will not be informative if the methods and 
results are not reported clearly.  
Importantly, for a cost estimate to be transferable over setting and time, analysts and users require 
transparency about its components, any assumptions made, its uncertainty and its limitations. 
Specifically, it needs to be clear how an intervention cost is constructed from its components, 
commonly: data on service use, the unit costs of that use, and the quantity and prices of inputs that 
determine that unit cost. This will allow analysts in other settings to adjust for differences in prices 
or other factors that affect the cost of delivery84. This clarity is also required to meet the minimum 
academic standard of replicability.  
To facilitate the transfer of costs across setting or time, a clear description of setting is also 
important. For example, economies of scope and scale often affect cost85, so understanding the 
coverage and integration will assist others in applying the cost estimate elsewhere. In addition, 
providing breakdowns of cost by activity may assist those adapting the intervention to their setting 
in identifying where they may have some activities already in place, or help in the financial planning 
of scale-up.  
Finally, given the levels of public investment in these data, there are increasing requests for the full 
dataset to be provided using open access facilities, and it is good research practice to declare 
conflicts of interest. 
 
Method specification  
 
The Reference Case details ‘Minimum Reporting Standards’ in the next section, which outline the 
aspects that need to be reported to ensure minimal compliance with the transparency principle. 
These reporting standards reflect the method specifications provided above and state that the 
purpose of the costing should be fully and accurately described, that the choice of costing to address 
the purpose should be justified, and that the intervention and context should be clearly 
characterized. The limitations of any method and their likely effect on a specific estimate should be 
fully transparent and, as with any scientific report, declarations of conflicts of interest should be 
made.  
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The transparency principle applies both to the reporting of costs, and to the intervention or the 
site characteristics (or other units of observation) to enable others to interpret whether the costs 
would be relevant for their setting.   
Where total costs are reported, both the number of units and the unit cost should also be reported. 
Where intervention unit costs per person are composed of unit costs for services (e.g., visit costs) 
multiplied by service use (e.g., number of visits), these ‘P’s (‘prices’) and ‘Q’s (‘quantities’) should be 
reported. If feasible, Ps and Qs should also be reported for inputs (e.g., staff numbers and wages). 
However, in some cases where only expenditures are known, this may not be possible. 
Even if other units are used, reporting should at a minimum be done using standardized unit costs 
where available. This Reference Case includes examples of standardized reporting formats for TB 
and HIV services that include a list of units for standardized unit costs.  
Where relevant cost data are reported, disaggregation should be provided by site (or measures of 
dispersion presented) and by input and activity.  
These should be considered minimum reporting standards to ensure minimal compliance with the 
transparency principle. Minimum Reporting Standards do not impose any additional methodological 
burden on researchers as they draw on information and data that must normally be considered in 
estimating costs. 
Finally, it is strongly recommended that analysts feed the results back to the sites and organizations 
from whom data has been collected. This can create buy-in and provides an additional process of 
validation to any results. 
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EXAMPLE OF APPLICATION OF REPORTING AND ANALYSIS PRINCIPLES 
 
 
Example #1: 
Avahan 
PRINCIPLE 15 - The cost of 
the intervention for sub-
populations and other 
areas of heterogeneity 
should be explored  
PRINCIPLE 16 - The 
uncertainty associated 
with cost estimates 
should be appropriately 
characterized.  
PRINCIPLE 17 - Cost estimates should be 
communicated clearly and transparently to 
enable decision-maker(s) to interpret and use 
the results.  
Limitations 
Generalizability 
Conflicts of interest 
Open access 
Sub-groups 
Cost functions Assessment of bias 
Have I explored any 
differences in cost by sub-
population? 
Have I understood the 
uncertainty of my cost 
estimates? 
Have I communicated all methods clearly and 
transparently? 
No conflicts of 
interest 
Limitations due to 
top-down methods 
By sex worker 
typology 
Cost function 
analysis 
Probabilistic 
sensitivity analysis 
Example #2: 
Planning 
scale-up of 
XPERT for TB 
diagnosis in 
South Africa 
Have I explored any 
differences in cost by sub-
population? 
Have I understood the 
uncertainty of my cost 
estimates? 
Have I communicated all methods clearly and 
transparently? 
MDR-TB vs DS-TB 
No statistical 
analysis 
Sensitivity analysis 
around pricing 
Previous funding 
from FIND 
(developers of 
Xpert) 
No above service 
delivery costs 
Statistical methods 
to establish 
difference 
Determinants of 
costs 
Univariate 
sensitivity analysis 
Multivariate 
sensitivity analysis 
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APPENDIX 1 - GLOSSARY 
 
Capital costs are one-time costs for items that have a useful life of over one year – such as buildings, 
vehicles or medical equipment.  
Cost is a general term that refers to the value of resources/inputs used to produce a good or service. 
This can refer to financial, economic, unit or average, or other types of costs depending on the 
ingredients included (see below). Costs may be incurred by health care providers (provider costs), 
but may also include costs incurred by patients or society (societal costs). 
Cost function shows the relationship between costs and components of cost (e.g., personnel, 
capital) or cost and the determinants/drivers of costs (e.g., scale, coverage, type of provider, time 
etc.). 
Discount rate is the rate at which future costs are discounted to account for time preference. 
Economic costs (aka opportunity costs) reflect the full value of all resources utilized in producing a 
good or service. Economic costs reflect “opportunity costs” since they represent resources 
consumed, that thus forgoes the opportunity to devote those resources to another purpose.  
Economies of scale occur when long-run average cost decreases as output increases. After minimum 
efficient scale is achieved, long-run average cost may increase (diseconomies of scale). Economies of 
scale are also used in some texts to describe any decrease in average cost associated with site size or 
scale, even where some costs are fixed (short run). In other texts this is referred to instead as 
‘economies of capacity’. 
Economies of scope occur when average costs decrease when services are jointly produced, 
compared to when they are produced separately. 
Expenditures reflect the financial outlay that an agent (e.g., government, donor or individual) 
spends during a period of time for goods and services. Expenditures can refer to the entire sum 
required by specified health services, or it may pertain only to those outlays incurred by a subset of 
the organizations involved in delivering the service. For example, the PEPFAR Expenditure Analysis 
initiative focuses only on that portion of costs that are incurred by PEPFAR. Note that expenditure 
data are usually reported using the cash basis method of accounting, that is, no amortization to 
capital goods is applied; all capital goods expenditures are recorded in full as they are incurred.  
Financial costs reflect financial outlays for goods and services needed to carry out a public health or 
medical intervention (in the context of global health), and as such are similar to expenditures. 
However, in contrast to expenditure data, financial costs depreciate capital expenditures over time.  
Fixed costs are those costs that do not vary with scale (changes in the level of output). These costs 
would be incurred even if the output were zero. Common examples include items such as buildings 
and equipment, but “fixity” depends on context even for personnel, as noted in the text. 
Incremental cost is a positive difference in cost between interventions or different amounts of an 
intervention.  
Gross cost is a costing approach where input use is estimated in total across all inputs. Gross costing 
is a contrast to micro-costing, which estimates the costs of each input separately. 
Marginal cost is the cost of producing one or more unit(s) of a service/output.  
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Non-traded goods are services and commodities that cannot be traded on the international market.  
Overhead costs refer to costs that cannot be directly traced to the provision of a service, such as 
administration, security personnel, buildings and general equipment. These costs may be referred to 
in some texts as indirect costs. Due to terminology confusion, the Reference Case recommends use 
of the term “operational” activity cost. 
Recurrent costs are the value of resources/inputs with useful lives of less than one year. This 
includes supplies and personnel. 
Start-up costs are the one-time commitment of resources required to establish a program to the 
point where service delivery can begin. Some of these resources may be donated or subsidized; thus, 
the financial costs may be less than the full economic costs. Start-up costs typically include some 
capital costs, but also include activities related to planning, staff training, materials development, 
infrastructure expansion, legal fees, or personnel recruitment. Some start-up costs should be 
amortized; for example, if staff training needs to be repeated every five years, training costs would 
be spread over five years. 
Sunk costs are costs that have already been incurred and that cannot be retrieved. For example, the 
depreciation of an asset (say, a CAT scanner) that occurs from the moment of purchase to some 
future date is sunk from the perspective of that future date.  
Unit costs (aka average costs) are the mean cost of producing one unit of a good or service, dividing 
total costs by total output in a specified time period. For example, if an HIV treatment program costs 
$1 million annually to provide 1,000 patient-years of ART, the unit cost would be $1,000 per patient-
year. Unit cost is thus the average cost per unit of service of a particular type of good or service.  
Variable costs are those costs that vary with scale (changes in the level of output). An example is 
expendable supplies such as test kits in an HIV counseling and testing program. Service delivery 
personnel costs are usually considered variable, since a substantial increase in caseload will require 
more staff, though small increases can often be accommodated within the existing staffing pattern.  
Shadow price is the estimated price of a good or service for which no market price exists. As noted 
in the text, there is another meaning for this phrase in optimization analyses. 
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APPENDIX 2 – PRINCIPLES AND METHODS REPORTING CHECKLIST 
 
We recommend use of this table for reporting methods. For a specific costing study, the “Options” 
column should be completed according to how the study was conducted. 
  
Reference Case Checklist Items Options 
STUDY DESIGN AND SCOPE 
Principle 1 - The purpose of the study, the population, and the intervention and/or service/output 
being costed should be clearly defined. 
Purpose 
Purpose type: 
Economic evaluation, Financial Planning, 
Budget Impact Analysis, Efficiency Analysis, 
Other 
Relevance for health practice and/or policy 
decisions: 
Free text 
Aim of the cost analysis: Free text 
Intended user(s) of the cost estimate: Free text 
Intervention 
Main activities/technologies involved: Free text 
Target population: 
As relevant: age, gender, geographical 
location, clinical indication 
Coverage level: Percentage of target population or sites 
Delivery mechanism (e.g., health system level, 
facility type, ownership, etc.): 
As relevant: level of health service, facility 
type 
Epidemiological context (i.e., incidence/prevalence 
of disease) 
As relevant: incidence and/or prevalence 
Intervention 
Describe production process (e.g., list main 
activities and key technologies involved in 
delivering the intervention) 
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Principle 2 - The perspective (extent of the resource use captured) of the cost estimation should 
be stated and justified relevant to purpose. 
Study perspective (e.g., provider, health system, societal, 
household): 
(Named) provider or societal, and list specific 
payers. State any stopping rules. 
Principle 3 - The type of cost being estimated should be clearly defined, in terms of economic vs financial, 
real world vs guideline, and incremental vs full cost, and whether the cost is 'net of future cost', should be 
justified relevant to purpose. 
Defining the cost 
Economic vs. financial cost Economic vs. financial cost 
Real world' vs guideline cost Real world' vs guideline cost 
Full vs incremental cost Full vs incremental cost 
Net of future cost Yes or No 
Principle 4 -  The ‘units’ in the unit costs for strategies, services and interventions should be defined, 
relevant for the costing purpose, and generalizable.   
List the unit costs used Choose from list of standardized unit costs 
Describe any adjustments made to reflect the quality of 
service output 
Choose from list of standardized adjustments 
Principle 5 - The time horizon should be of sufficient length to capture all costs relevant to the purpose, and 
consideration should be given to disaggregating costs into separate time periods where appropriate. 
Time period 
Period type (start-up vs implementation): Start-up, implementation or both 
Time period: Years and months 
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SERVICE AND RESOURCE USE MEASUREMENT 
Principle 6 - The scope of the inputs to include in the cost estimation should be defined and justified 
relevant to purpose. 
Defining the scope 
Above service delivery costs included Yes or No 
Costs of supporting change included Yes or No 
Research costs included Yes or No 
Unrelated costs included Yes or No 
If incremental costs, assumptions made for existing 
capacity 
Free text 
Any exclusions other to scope Free text 
Principle 7 - The methods for estimating the quantity of inputs should be described, including data sources 
and criteria for allocating resources. 
Describe the measurement of each input as either top-
down or bottom-up 
Top down or bottom-up 
Describe method to allocate human resources inputs 
Observation, time sheets, work-sampling, 
interviews, other 
Describe methods to allocate above site/overhead inputs Method, criteria and data source for criteria 
Describe the methods for excluding research costs Method, criteria and data source for criteria 
Describe the methods for measuring other resources Method and data source 
Principle 8 - The sampling strategy used should be determined by the precision demanded by the costing 
purpose and designed to minimize bias. 
Site/client selection process/criteria 
Describe geographic sampling (if applicable) Frame and method 
Describe site sampling (if applicable) Frame and method 
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Describe patient sampling (if applicable) Frame and method 
Describe methods to calculate sample size Calculation 
Principle 9 - The selection of the data source(s) and methods for estimating service use should be described, 
and potential biases reported in the study limitations.    
Identify the data source used to measure the units 
Case note extraction, patient interviews, 
provider interviews, routine information 
systems, claims data, other 
Where relevant describe the sampling frame, method 
and size: 
Free text 
Describe any method used to fill missing data Free text 
Principle 10 - Consideration should be given to the timing of data collection to minimize recall bias and, 
where relevant, the impact of seasonality and other differences over time. 
The timing of data collection should be specified in the following ways: 
Timing of data collection (resource and service use) Date of data collection 
Prospective or retrospective Prospective or retrospective 
Longitudinal vs cross-sectional data Longitudinal vs cross-sectional data 
Recall period, where relevant Months or weeks 
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VALUATION AND PRICING 
Principle 11 - The sources for price data should be listed by input, and clear delineation should be made 
between local and international price data sources, and tradeable, non-tradeable goods. 
Report the sources of price data by input Ministry of Health, local market, etc. 
Report inputs where local and international prices were 
used 
Local or international 
Principle 12 - Capital costs should be appropriately annuitized or depreciated to reflect the expected life of 
capital inputs. 
Describe the depreciation approach  Straight line depreciation, amortization 
Describe any discount rate used for capital goods Percentage 
Report the expected life years of capital goods, and data 
sources 
Years and free text 
Principle 13 - Where relevant an appropriate discount rate, inflation and exchange rates should be used, 
and clearly stated. 
Describe any discount rate used for future costs Percentage 
Describe the reported currency year Currency and Year 
Describe any conversions made Exchange rate, Source and Year 
Report the inflation type and rate used Percentage, GDP deflator/ CPI, Source 
Principle 14 - The use and source of shadow prices for goods and for the opportunity cost of time should be 
reported.  
Methods for valuing the following should be reported:  
Report methods for valuing volunteer time Free text 
Report adjustments for input prices (donated or 
subsidized goods) 
Free text 
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ANALYSING AND PRESENTING RESULTS 
Principle 15 - Variation in the cost of the intervention by site size/ organization, sub-populations, or by other 
drivers of heterogeneity should be explored and reported. 
Describe any sub-groups or populations analyzed Free text 
Describe any statistical methods used to establish 
differences in unit costs by sub-group 
Free text 
Describe any determinants of cost (model specification) Free text 
Describe any multivariate statistical methods used to 
analyze cost functions 
Free text 
Principle 16 - The uncertainty associated with cost estimates should be appropriately characterized. 
Describe sensitivity analyses conducted Free text 
List possible sources of bias  Free text 
Principle 17 - Cost estimates should be communicated clearly and transparently to enable decision-maker(s) 
to interpret and use the results.  
Limitations 
Limitations in the design, analysis, and results Free text 
Aspects of the cost estimates that would limit 
generalizability of results to other constituencies 
Free text 
Conflicts of Interest 
All pecuniary and non-pecuniary interests of the study 
contributors 
Free text 
All sources of funding that supported conduct of the 
costing 
Free text 
Non-monetary sources of support for conduct of the 
costing 
Free text 
Open access 
Dataset available Yes or No 
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APPENDIX 3 – STANDARDIZED TB UNIT COSTS  
 
List of standardized TB unit costs by intervention 
Intervention 
class 
Intervention 
 
Intervention 
Details 
 
Technology 
 
Platform 
(choose more 
than one only 
when 
necessary) 
Population 
(choose more than one only 
when necessary) 
STANDARD UNIT 
COST INTERVENTION                                                
(quality-adjusted unit 
cost) 
STANDARD UNIT 
COST SERVICE 
DIRECT 
STANDARD UNIT 
COST SERVICE 
ANCILLARY 
TB case 
detection 
and 
diagnosis 
Passive Case 
Finding (PCF) 
Screening and 
diagnosing  
active and 
latent TB in 
those who 
report to TB 
services with 
symptoms 
 
Symptom screen 
Xpert MTB/RIF 
Sputum induction 
Microscopy (LED) 
Microscopy (ZN) 
Culture (solid media) 
Culture (liquid media) 
X-ray 
Digital X-ray 
Rapid HIV Test 
LPA - FLD 
LPA - SLD 
DST (solid media) 
DST - FLD (liquid media) 
DST - SLD (liquid media) 
LAMP 
LF-LAM 
IGRA* 
TST 
Fine needle biopsy 
Bronchial lavage 
Gastric lavage 
Aspirates (EPTB) 
CT scan (EPTB) 
Ultrasound (EPTB) 
 
Public facility 
(TB care) 
Private facility 
(TB care) 
Children  
Adults (HIV+, HIV-) 
Adults (pulmonary/ extra-
pulmonary) 
Adults (DS, MDR, pre-XDR, 
XDR) 
Cost per person 
diagnosed DS-TB 
Cost per person 
diagnosed DR-TB 
Cost per TB case 
diagnosed 
Cost per outpatient 
visit 
Cost per inpatient 
visit (e.g., for 
children needing 
fine-needle biopsy) 
Cost per test 
Cost per sample/ 
slide 
Cost per person 
patient support 
Cost per PPM activity 
TB: tuberculosis; MTB: Mycobacterium tuberculosis; RIF: rifampicin; LED: light-emitting diode; ZN: Ziehl Neelsen; LPA: line probe assay; FLD: first-line drug; SLD: second-line drug; DST: drug-susceptibility testing; 
LAMP: loop-mediated isothermal amplification; LF-LAM: lateral flow urine lipoarabinomannan assay; IGRA: interferon-gamma release assay; TST: tuberculin skin test; EPTB: extra-pulmonary tuberculosis; CT: 
computed tomography; HIV: human immunodeficiency virus; DS: drug-sensitive; MDR: multidrug-resistant; XDR: extensively drug-resistant; PPM: public-private mix 
*IGRA is not recommended for detection of latent TB infection in WHO Guidelines but is being used in some settings.  
P a g e  | k 
 
 
Intervention 
class 
Intervention 
 
Intervention 
Details 
 
Technology 
 
Platform 
 
Population 
 
STANDARD UNIT 
COST 
INTERVENTION                                                
(italics add any 
quality-adjusted 
unit cost) 
STANDARD UNIT COST 
SERVICE DIRECT 
STANDARD UNIT 
COST SERVICE 
ANCILLARY 
TB case 
detection 
and 
diagnosis 
Intensified 
case finding 
(ICF) 
Detect potential 
active and latent 
TB among people 
living with HIV or 
in other high-risk 
populations 
receiving non-TB 
health care 
(diabetes, 
maternal and 
child health 
clinics) 
 
Symptom Screen  
Xpert MTB/RIF 
Microscopy (LED) 
Microscopy (ZN) 
X-ray 
Digital X-ray 
Rapid HIV Test  
Culture (solid media) 
Culture (liquid media) 
LPA - FLD 
LPA - SLD 
DST (solid media) 
DST - FLD (liquid media) 
DST - SLD (liquid media) 
LAMP 
LF-LAM 
IGRA* 
TST  
Fine Needle Biopsy 
Bronchial lavage 
Gastric lavage 
Aspirates (EPTB) 
CT scan (EPTB) 
Ultrasound (EPTB) 
 
Public facility 
(different 
departments) 
Private facility 
(different facilities) 
Adults (HIV+) 
Other high-risk groups 
attending health facilities 
Cost per person 
screened  
Cost per person 
diagnosed 
Cost per TB case 
diagnosed 
Cost per screen 
(different platforms and 
approaches) 
Cost per outpatient visit 
Cost per inpatient visit 
Cost per household visit 
Cost per triage test 
Cost per diagnostic test 
Cost per sample/slide 
Cost per patient 
support (per visit, 
screen or 
diagnosis) 
Cost per PAL 
activity 
Cost per PPM 
activity 
PAL: Practical Approach to Lung Health 
*IGRA is not recommended for detection of latent TB infection in WHO Guidelines but is being used in some settings. 
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Intervention 
class 
Intervention 
 
Intervention 
Details 
 
Technology 
 
Platform 
 
Population 
 
STANDARD UNIT 
COST 
INTERVENTION                                                
(italics add any 
quality-adjusted 
unit cost) 
STANDARD UNIT COST 
SERVICE DIRECT 
STANDARD UNIT 
COST SERVICE 
ANCILLARY 
TB case 
detection 
and 
diagnosis 
Active Case 
Finding (ACF) 
Screening and 
diagnosing active 
and latent TB in 
those who are 
not in public 
health care  
 
Symptom Screen 
Xpert MTB/RIF 
Microscopy (LED)  
Culture (solid) 
Culture (liquid) 
X-ray 
Digital X-ray 
Rapid HIV Test 
Contact tracing 
LPA 
DST 
IGRA* 
TST  
Fine Needle Biopsy 
Bronchial lavage 
Gastric lavage 
Aspirates (EPTB) 
CT scan (EPTB) 
Ultrasound (EPTB) 
 
Household  
Mobile 
Prisons 
Schools (through 
health facility 
outreach) 
 
Household contacts: 
Adults 
Children under 5 
Children 5-18 
Prisoners 
Poor urban populations 
(slums) 
Mobile and migrant 
populations 
Private providers 
Occupational groups 
(miners, health-care 
workers, etc.) 
Cost per person 
screened  
Cost per person 
diagnosed 
Cost per TB case 
diagnosed 
Cost per screen 
(different platforms and 
algorithms) 
Cost per outpatient visit 
Cost per inpatient visit 
Cost per mobile clinic 
visit 
Cost per household visit 
Cost per other visit 
Cost per triage test 
Cost per diagnostic test 
Cost per sample/slide 
Cost per patient 
support (per visit, 
screen or 
diagnosis) 
Cost per 
community event 
*IGRA is not recommended for detection of latent TB infection in the WHO Guidelines but is being used in some settings.  
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Intervention 
class 
Intervention 
 
Intervention 
Details 
 
Phase 
 
Technology 
 
Platform 
(choose more 
than one only 
when 
necessary) 
Population 
(choose more than one only 
when necessary) 
STANDARD UNIT 
COST INTERVENTION                                                
(quality-adjusted unit 
cost) 
STANDARD UNIT 
COST SERVICE 
DIRECT 
STANDARD UNIT 
COST SERVICE 
ANCILLARY 
TB treatment  TB Treatment  
Treatment of 
active TB with 
observation and 
possibly patient 
support 
Intensive 
Continuation 
First-line treatment 
Retreatment 
Second-line treatment 
Third-line treatment 
Palliative care 
Monitoring tests (for 
status, adverse events 
and nutritional 
assessment) 
Follow up of defaulters 
M-health 
ART regimen if HIV+ 
Household 
Community 
Public facility 
Private facility 
Hospital general 
Hospital TB 
Children 
Adults (HIV+, HIV-) 
Adults (pulmonary/ extra-
pulmonary) 
Adults (DS, MDR, pre-XDR, 
XDR) 
 
Cost per treatment 
month DS-TB 
Cost per treatment 
month MR-TB/ 
Cost per treatment 
month PDR-TB/ 
Cost per treatment 
month MDR-TB/ 
Cost per treatment 
month pre-XDR-TB/ 
Cost per treatment 
month XDR-TB 
Cost per person 
treated 
Cost per person 
completing treatment 
Cost per treatment 
monitoring 
 
Cost per outpatient 
visit 
Cost per inpatient 
bed-day 
Cost per DOT visit 
community 
Cost per microscopy 
Cost per other test 
Cost per DS-TB 
regimen 
Cost per short DR-
TB regimen 
Cost per long DR-TB 
regimen 
Cost per person 
month patient support 
Cost per person 
patient support 
Cost per patient 
support visit 
Cost per community 
event 
M-health: mobile health; ART: antiretroviral therapy; MR: mono-resistant; PDR: poly-drug resistant; DOT: directly observed treatment  
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Intervention 
class 
Intervention 
 
Intervention 
Details 
 
Technology 
 
Platform 
(choose more 
than one only 
when 
necessary) 
Population 
(choose more than one only 
when necessary) 
STANDARD UNIT 
COST INTERVENTION                                                
(quality-adjusted unit 
cost) 
STANDARD UNIT 
COST SERVICE 
DIRECT 
STANDARD UNIT 
COST SERVICE 
ANCILLARY 
TB 
prevention 
TB Prevention  
Treatment to 
prevent active TB 
 
6H 
Lifelong H 
3HP 
Rifapentine 
TB screen to rule out 
active 
IGRA 
TST 
Monitoring tests 
(breakthrough disease, 
adverse events and 
acquired drug 
resistance) 
ART regimen 
Cotrimoxazole 
prophylaxis 
 
Public facility 
(HIV care) 
Public facility 
Private facility 
Hospital general 
Hospital TB 
Children 
Adults (HIV+) 
Cost per treatment 
month LTBI 
Cost per person 
treated LTBI 
Cost per person 
completing treatment 
LTBI 
Cost per outpatient 
visit 
Cost per screen 
Cost per test 
Cost per regimen 
Cost per person 
month patient support 
Cost per person 
patient support 
Cost per patient 
support visit 
Cost per community 
event 
H: isoniazid; P: Rifapentine; LTBI: latent TB infection  
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Intervention 
class 
Intervention 
 
Intervention 
Details 
 
Technology 
 
Platform 
(choose more 
than one only 
when 
necessary) 
Population 
(choose more than one only 
when necessary) 
STANDARD UNIT 
COST INTERVENTION                                                
(quality-adjusted unit 
cost) 
STANDARD UNIT 
COST SERVICE 
DIRECT 
STANDARD UNIT 
COST SERVICE 
ANCILLARY 
TB infection 
control 
TB infection 
control 
Administrative, 
environmental 
and personal 
protection to 
prevent infection 
in health facilities 
and laboratories 
Protective equipment and 
supplies 
Biosafety in laboratories 
Environmental 
(ventilation/UV lights) 
Administration/ patient 
Public facility 
Private facility 
Hospital general 
Hospital TB 
Health care workers 
Patients 
Accompanying 
family/friend/supporter/DOT 
observer 
Laboratory staff 
Cost per facility 
Cost per laboratory 
  
  
Activity unit costs 
 
Costs per laboratory 
specification 
Cost of safety 
equipment 
Cost of personal 
protective equipment 
Cost of waste handling 
Cost per safety 
training 
Cost of codes and 
SOPs  
 
UV: ultraviolet; SOP: standard operating procedure  
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Intervention 
class 
Intervention 
 
Intervention 
Details 
 
Technology 
 
Platform 
(choose more 
than one only 
when 
necessary) 
Population 
(choose more than one only 
when necessary) 
STANDARD UNIT 
COST INTERVENTION                                                
(quality-adjusted unit 
cost) 
STANDARD UNIT 
COST SERVICE 
DIRECT 
STANDARD UNIT 
COST SERVICE 
ANCILLARY 
TB policy, 
planning, 
coordination 
and 
management 
TB policy, 
planning, 
coordination 
and 
management 
Policy, planning, 
coordination and 
management for 
TB services 
 
National meetings 
Regional meetings 
Supervision 
Management and 
Information Systems 
Surveys 
Procurement and supply 
chain management 
Advocacy 
Technical assistance 
Training 
Accreditation and QA for labs 
Transport for specimens 
Community Media/ IEC 
Partnership Activities 
 
National TB 
Program 
Ministry of 
Health 
Public health 
facilities and 
laboratories 
Private health 
facilities and 
laboratories 
Non-
governmental 
organizations 
 
Health-care workers 
Laboratory staff 
Management 
Cost per program   
Activity unit costs 
 
Costs per training 
Costs per software 
development 
Cost per event 
Cost per workshop 
Cost per supervisory 
visit 
Cost per item 
transported 
QA: quality assurance; IEC: information; education and communication 
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Figure: Outline of how standardized TB unit costs related to one another (and relevant P’s and Q’s) by intervention 
a) Passive case finding 
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b) Intensified case finding 
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c) Active case finding 
 
* Activities can occur at health facilities, as outreach, mobile or household visits. 
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d) TB treatment: first-line and retreatment 
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e) TB treatment: second and third-line (facility based) 
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f) TB treatment: second and third-line (community based) 
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g) Prevention: active TB 
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h) Infection control: health facility 
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i) Infection control: laboratory 
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j) Policy, planning, coordination and management 
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